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Abstract 
The current batch potency test for Leptospira interrogans serovar Canicola vaccines 
requires the use of a large number of hamsters and has severe effects; whilst effective, a 
safer, cheaper, more ethical replacement is desired.  The aim of this study was to 
determine the common components of commercially available serovar Canicola 
vaccines to aid development of an in vitro potency test; lipopolysaccharide and protein 
were chosen for analysis due to their known immunogenic properties. Analysis of five 
serovar Canicola vaccines (A-E)  using the Limulus amebocyte lysate assay and silver 
stained sodium dodecyl sulfate polyacrylamide gels, indicated that lipopolysaccharide 
was not detectable in all vaccines tested preventing it from being a suitable biomarker 
for an in vitro test. Therefore the protein contents of vaccines A-E were determined by 
two dimensional liquid chromatography mass spectrometry (221±31, 9±8, 34±4, 21±5 
and 34±17 proteins [mean ± 1 standard deviation] found respectively) to identify 
conserved proteins. The outer membrane protein LipL32 was shown to be common to 
vaccines A-E and to be present at a significantly higher (p≤ 0.05) relative spectral 
abundance in a batch of vaccine which passed the in vivo potency test, compared to one 
which failed. Quantitative analysis using multiple reaction monitoring determined that 
the concentration of the N terminus of LipL32 was significantly lower (p≤ 0.01) in 
failed batches (n=2) of vaccine compared to passed batches (n=2); the concentration of 
the C terminus was relatively uniform. The protective effect of LipL32 against serovar 
Canicola was subsequently investigated in hamsters. Decreased kidney invasion was 
observed in groups vaccinated with LipL32 prior to challenge suggesting that LipL32 
may be an active component of vaccines A-E. With additional supportive data, beyond 
the scope of this study, quantitative analysis of N terminal LipL32 has the potential to 
form an in vitro vaccine potency test.  
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Chapter 1  Introduction 
1.1 History and Clinical importance of Leptospirosis Infection 
1.1.1 Discovery of Leptospirosis 
The discovery of Leptospirosis is generally ascribed to Adolf Weil who, in 1886, 
accurately identified the clinical symptoms of the disease (Alston and Brown, 1937). 
Weil’s name is now so synonymous with the disease that the term ‘Weil’s disease’ is 
often erroneously used to describe infection with Leptospira interrogans (L. 
interrogans), regardless of the severity of the symptoms, when in fact it should only be 
used following the presentation of jaundice (Hill and Sanders, 1997). A disease 
matching the symptoms of Leptospirosis was described prior to 1886 (Levett, 2001) 
suggesting the disease had been prevalent for some time before its official ‘discovery’. 
A recent paper (Marr and Cathey, 2010) has even suggested that Leptospirosis played a 
role in the demise of the Native American population of Massachusetts during the early 
17th century. 
 
It was noted early on that people who worked in close proximity to stagnant water such 
as in sewers or rice fields were prone to Leptospirosis. But it was not until 1915 that the 
bacteria were first isolated from the hepatic tissue of an infected guinea pig, which 
allowed Leptospiras route of infection and morphology to be determined (Inada et al., 
1916).  
 
 
1.1.2 Taxonomy 
Currently serological differentiation is the most practical system used to categorise 
Leptospira. This involves using either the cross agglutination absorption test (CAAT) or 
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the microscopic agglutination test (MAT) to discriminate between Leptospira based on 
their antigen reactivity. Over 230 pathogenic serovars of Leptospira have been 
identified to date (Adler et al., 2011); antigenically related serovars are often assembled 
into serogroups. 
 
In addition to this, a genetic classification system has also been developed based on 
DNA hybridisation studies; to date 20 species have been identified (Table 1) (Cerqueira 
and Picardeau, 2009). Some of these species can be clearly grouped as either pathogenic 
or non-pathogenic (Table 1); however a consensus regarding the pathogenicity of L. 
broomii, L. fainei, L. inadai, L. licerasiae and L. wolffii has yet to be determined 
resulting in their current ‘intermediate’ classification (Table 1). 
 
Table 1: Current known species of Leptospira spp. (Cerqueira and Picardeau, 2009). 
Pathogenic Intermediate Non- Pathogenic 
L. alexanderi (genomospecies 2) L. broomii L. biflexa 
L. alstonii (genomospecies 1) L. fainei L. kmetyi 
L. borgpetersenii L. inadai L. meyeri 
L. interrogans L. licerasiae L. terpstrae (genomospecies 3) 
L. kirschneri L. wolffii L. vanthielii (genomospecies 4) 
L. noguchii  L. wolbachii 
L. santarosai  L. yanagawae (genomospecies 5) 
L. weilii   
 
The new genetic classification system is of benefit as it puts Leptospira taxonomy in 
line with other species and thus allows more direct comparison in the literature. 
However, it was also reported that some serovars could belong to more than one 
species, thus making the two classification systems disparate (Levett, 2001). 
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1.1.3 Epidemiology 
As a zoonotic, the primary route of infection for most humans is either through direct 
contact with infected animals or by exposure to water contaminated with their urine. 
Routes of entry into the host include ingestion, direct entry into the blood stream via 
cuts and inhalation of aerosols (Woodward, 2001). 
 
The typical hosts of Leptospira include rodents, cattle, dogs, pigs, and sheep, although 
virtually any mammal is a potential carrier (Koizumi and Watanabe, 2009). Infection in 
dogs can often be asymptomatic (McDonough, 2001), which is of particular concern 
due to their status as companion animals as it increases the likelihood of human 
infection. Virtually all human infection occurs through contact with animals (Adler and 
de la Pena Moctezuma, 2010) which has led to its classification as a zoonotic, although 
transfer of Leptospira between humans can also occur in rare circumstances (Thornley 
et al., 2002). Transmission itself is dependent on a number of factors including climate 
(warmer, more humid environments provide better growth conditions), the population 
density and the frequency of contact with infected hosts (Levett, 2001). Global warming 
(Desai et al., 2009) alongside other ecological changes (Lau et al., 2012) has been 
associated with altering the epidemiology of the bacteria resulting in the emergence of 
previously unknown serovars. 
 
Infection in dogs is closely monitored in the UK due to their status as companion 
animals; in 2010, 3407 canine serum samples were submitted to the Animal Health and 
Veterinary Laboratories Agency (AHVLA) for testing (Defra, 2010). Of these 1199 
samples (35.2% of canine samples) were identified as positive for L. interrogans 
serovar Canicola. Incidence of human infection in the UK is typically fairly low (Table 
2); although it should be noted that these figures only represent cases confirmed by the 
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Leptospirosis reference unit (Health Protection Agency, UK). Serotyping is required for 
accurate diagnosis, which many third world countries do not have access to; this in 
conjunction with Leptospiras limited public profile often leads to misdiagnosis and 
general underreporting of infection. 
 
A higher prevalence of some serovars has been observed in particular species (Bharti et 
al., 2003), such as serovar Canicola in dogs and serovar Hardjo in sheep and cattle. This 
serovar-host predisposition can aid in tracking the spread of the disease and helps 
determine which serovar should be vaccinated against in particular animal populations. 
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Table 2: Confirmed reports of Leptospirosis in UK residents 1996-2010 (Defra, 2008, Defra, 2010). 
Year Country 
1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 
Scotland 0 1 1 0 0 0 3 0 2 4 3 6 13 2 3 
England/Wales 22 39 29 41 54 48 54 28 29 41 44 74 62 52 39 
N. Ireland 2 3 4 1 0 0 1 0 1 1 4 1 1 0 0 
UK 24 43 34 42 54 48 58 28 32 46 51 81 76 54 42 
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1.2 Leptospira Spp. 
1.2.1 Physical  Characteristics 
Leptospires are gram negative helically coiled spirochetes with a high motility due to 
the presence of two periplasmic flagella (Figure 1). They typically measure between 6-
20 µm long and 0.1 µm wide (Levett, 2001) and have a ‘hooked’ end resembling a 
question mark. In addition to the hooked form a ‘straight’ form of the bacteria exists, 
this straight form is often associated with a loss of virulence and thought to be a result 
of laboratory culture; however, no clear link between morphology and virulence has so 
far been established (Woodward, 2001, Faine and Vanderhoeden, 1964). 
 
 
Figure 1: Electron micrograph of Leptospira spp. taken from Collins (2006). 
 
Leptospira have an outer membrane principally consisting of lipopolysaccharide (LPS) 
and proteins; with LipL32, LipL36, LigA, LigB, Loa22 and OmpL1 being amongst the 
most abundant proteins (Figure 2). The diversity of LPS found on the outer membrane 
allows different variants of Leptospira to be categorised (de la Pena-Moctezuma et al., 
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1999) based on their reaction to established serological tests resulting in the various 
different serovars. 
 
 
Figure 2: Diagram of the membrane architecture of Leptospira spp. (Fraga et al., 2011).  
Key: LPS= Lipopolysaccharide, OM= Outer membrane, IM= Inner membrane and PG= 
Peptidoglycan. TonB dependant receptor systems, endoflagella and lipoprotein export apparatus 
have been omitted for simplicity. 
 
Leptospira spp. requires very exact conditions in order to grow in vitro which can vary 
between serovars. However, broadly speaking, most pathogenic serovars can be grown 
at 30oC in EMJH medium with a typical doubling time of approximately 14-18 hours 
and an optimum pH of 7.2-7.6 (Woodward, 2001); non-pathogenic strains are less 
fastidious and so are able to be grown at 13oC (Levett, 2001), which allows easy 
distinction between the two (Johnson and Harris, 1967). The EMJH media currently 
used is based on the polysorbate 80 media, containing ammonium chloride, albumin, 
vitamin B12 and thiamine, first described by Ellinghausen and McCullough (1965); a 
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key component for culturing Leptospira in vitro is the presence of iron (Faine, 1959). 
Leptospira has a predisposition to lose virulence following in vitro culture (Haake et al., 
1991) and liquid nitrogen storage (Reed et al., 2000), due in part to alterations in the 
expression of lipopolysaccharide and outer membrane proteins (Haake et al., 1991) such 
as LipL36 (Haake et al., 1998) and LipL45 (Matsunaga et al., 2002), and therefore has 
to be routinely passed (passaged) through small mammals which are its natural reservoir 
(Rahelinirina et al., 2010). 
 
1.2.2 Genetic Characteristics 
Genetic sequencing of Leptospira has resulted in the publication of six genomes to date 
(Adler and de la Pena Moctezuma, 2010), which indicate that the Leptospira genome 
size varies between 3.9-4.6 Mb with a guanine: cytosine ratio of 35-41%, dependant on 
the precise species/serovar. A core genome between Leptospira interrogans, Leptospira 
borgpeteresenii and Leptospira biflexa, comprising of 2050 genes (Picardeau et al., 
2008), has also been identified using comparative genomics. Development of standard 
methods for genetic manipulation of Leptospira has proved difficult; however 
transposon mutagenesis has been successfully used to create mutants (Murray et al., 
2009) resulting in the identification of LPS, Loa22, haem oxygenase and FliY proteins 
as virulence factors (Fraga et al., 2011). 
 
1.2.3 Protein Characteristics 
Protein analysis is a useful approach to quantitatively examine which proteins an 
organism is expressing at particular time points (referred herein as its proteome); this 
can aid in the understanding of biological processes in addition to providing target 
molecules for therapeutic and/or prognostic applications. To this end, the proteomes of 
L. interrogans serovars Copenhageni, Pomona and Lai have been determined using gel 
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and liquid chromatography based mass spectrometry approaches (Eshghi et al., 2009, 
Malmstrom et al., 2009, Vieira et al., 2009, Cao et al., 2010, Zhong et al., 2011b).  
 
The proteomes of virulent and lab attenuated (avirulent) strains of serovar Lai (strains 
56601 and IPAV respectively) have been directly compared to determine differences in 
protein expression (Zhong et al., 2011b). This concluded that differences in the 
expression of the outer membrane proteins OmpL1, LipL45, LipL48, LipL41 and 
LipL36 were responsible for the loss of virulence observed in the lab attenuated strain. 
 
In addition, the Leptospira proteins LipL32 (Haake et al., 2000, Seixas et al., 2007b), 
LipL41 (Haake et al., 1999), LipL45 (Sakolvaree et al., 2007), OmpL1 (Dong et al., 
2008), OmpA (Yan et al., 2010), LigA (Faisal et al., 2008) and LigB (Yan et al., 2009) 
have all been identified as potential vaccine targets and are actively being investigated 
for their immunological protective effects in vivo. 
 
1.3 Infection and Treatment 
1.3.1 Clinical features 
Upon entering the body Leptospira incubate for 7-12 days before entering the 
septicaemic phase (Collins, 2006). This is often characterised as ‘mild flu-like’ 
symptoms which can include: Fever, headache, myalgia, nausea, cough, diarrhoea and 
vomiting. This septicaemic phase typically lasts about a week wherein the initial 
symptoms begin to dissipate.  
 
After this preliminary phase the initial symptoms alleviate for a few days prior to the 
subject entering the immune phase of the disease. Common symptoms of this immune 
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phase (Howell and Cole, 2006), which can last in excess of 30 days, include meningitis, 
enlarged lymph nodes, hepatitis and cardiac arrhythmias. In extreme cases, the patient 
can go on to develop Weils disease which is characterised by hepatic and renal failure, 
fever, jaundice and/or pulmonary haemorrhage. In particularly rare cases, infection with 
Leptospira does not result in any obvious clinical symptoms (Ganoza et al., 2010) 
although the long term effects of this have yet to be determined. Presentation of 
Leptospirosis in animals can vary depending on the precise species. Renal and hepatic 
failure are particularly common in canines however pulmonary disorder such as 
dyspnoea are also prevalent (Kohn et al., 2010). Abortion of offspring is known to occur 
in cattle (Defra, 2008), swine (Ramos et al., 2006), sheep (Kingscote, 1985) and goats 
(Leon-Vizcaino et al., 1987) making the disease economically damaging to the farming 
industry. 
 
1.3.2 Diagnostics 
Due to the wide range of non-specific symptoms that Leptospira infection can induce it 
is often difficult to make an accurate diagnosis on clinical presentation alone. Typically 
the infection is detected in either a blood or urine sample but it is not uncommon for it 
to be found through a kidney biopsy.  
 
Rapid confirmation of the presence of Leptospira can be achieved through direct 
visualisation using dark field microscopy (Adler and de la Pena Moctezuma, 2010) for 
fluids or silver staining for tissues (Skilbeck and Chappel, 1987). However, for accurate 
determination of the specific serovar, molecular or serological tests must be performed. 
 
Molecular tests under development for more specific species, serovar and strain typing 
or identification include; multilocus sequence typing (MLST) (Ahmed et al., 2006),  
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real time polymerase chain reaction (Ooteman et al., 2006), insertion sequence typing 
(Cerqueira and Picardeau, 2009), 16s ribosomal RNA sequencing (Morey et al., 2006), 
pulsed field gel electrophoresis (PFGE) (Romero et al., 2009), restriction fragment 
length polymorphism (RFLP) (Turk et al., 2009), variable number tandem repeat 
(VNTR) (Majed et al., 2005), random amplification of polymorphic DNA (RAPD) 
(Ramadass et al., 1997), ribotyping (Kositanont et al., 2007) and more recently single 
nucleotide isolated polymorphism detection by denaturing high performance liquid 
chromatography (DHPLC) (Fenner et al., 2010). 
 
Due in part to the disparity between genetic and serological taxonomy the MAT tends to 
be the preferred choice for Leptospira typing, although its usage in developing countries 
is often precluded by access to antisera.  Other serological tests such as ELISA and 
CAAT tend to be less accurate (van de Maele et al., 2008) or too technically demanding 
in terms of time and expertise for routine diagnostic purposes (Cerqueira and Picardeau, 
2009) respectively. 
 
1.3.3 Infection and Immune Response   
Following initial exposure to infection (section 1.1.3) Leptospira can bind to 
extracellular matrix components, such as fibronectin (Chirathaworn et al., 2007), and 
have also been shown to bind to endothelial cells, macrophages, and fibroblasts in vitro 
(Fraga et al., 2011). Further they are able to quickly pass through cell monolayers 
(Barocchi et al., 2002), allowing them to disseminate to multiple organs.  
 
The involvement of the innate immune system against pathogenic Leptospira (Goris et 
al., 2011) has not been fully characterised; however it has been determined that 
Leptospira has the ability to evade the innate immune system of humans through 
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binding to the complement regulator C4BP (Barbosa et al., 2009). In addition the role of 
the cell mediated immune system against pathogenic Leptospira is also not fully 
understood (Fraga et al., 2011), although Leptospira is known to promote the apoptosis 
of macrophages (Jin et al., 2009). It is however well established that the principle 
immune response against Leptospira is humoral, due to the fact that immunity can be 
transferred from one host to another through serum (Adler and de la Pena Moctezuma, 
2010). Immunoglobulin M (IgM) has been determined (Hartman et al., 1984) to be the 
initial response to first vaccination with a serovar Canicola vaccine in dogs, however 
subsequent booster vaccinations result in higher levels of immunoglobulin G (IgG) 
(Hartman et al., 1984). 
 
1.3.4 Treatment 
If Leptospirosis infection is identified at an early stage, before severe tissue damage, 
antibiotics are an extremely effective treatment which can completely cure the subject. 
Penicillin, doxycycline, ampicillin and ceftriaxone being the most commonly used 
(Pappas and Cascio, 2006). In addition to this, antibiotics can be administered as a 
prophylactic (Illangasekera et al., 2008) to inhabitants of higher risk areas (victims of 
floods for example) to help prevent the spread of infection. However, in some cases of 
human infection, antibiotic treatment of Leptospira spp can result in Jarisch–
Herxheimer reactions (Maneewatch et al., 2009), whereby endotoxin is released due to 
the large number of organisms killed; this endotoxin causes a variety of additional 
symptoms including fever, making vaccination a preferable treatment strategy. 
Interestingly a recent study (Brett-Major and Coldren, 2012) was unable confirm that 
antibiotics statistically reduced the duration of infection. In the event of severe infection 
additional medical steps must be taken to improve the subject’s condition (dialysis for 
example is used following kidney damage). 
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1.3.5 Vaccines 
Although Leptospira infection can be treated (section 1.3.4), initial symptoms in cattle 
such as cessation of milk production and miscarriage (Defra, 2008), have often already 
occurred which are economically damaging to the farming community. Vaccination 
represents the most effective way of preventing infection and avoiding these symptoms. 
However, since Leptospira is predominantly found in wild animals, particularly rodents 
(Rahelinirina et al., 2010), it has not yet been possible to use vaccination to completely 
eradicate the bacteria from the environment. The strategy for disease prevention 
therefore relies heavily on the principle of herd immunity (Schultz et al., 2010), which 
relies on the vaccination of as many domestic and farm animals as possible to reduce 
the spread of infection. Dogs in particular are regularly vaccinated against Leptospira as 
part of their standard annual vaccination protocol. 
 
The majority of Leptospira vaccines currently available on the market (Table 3) are 
derived from inactivated or killed bacteria. The specific methodologies used to generate 
these vaccines are commercially sensitive and not in the public domain. However, in 
general, Leptospira vaccine manufacture involves growing the bacteria in an albumin 
rich media, such as EMJH, and then killing/inactivating the bacteria using either 
formalin or heat. Live attenuated vaccines for Leptospira have also been developed 
(Kenzy et al., 1961); however they are not in widespread use, presumably due to the 
risk of the strains regaining their pathogenicity and causing clinical symptoms in the 
host (Srivastava, 2006). Subunit vaccines, engineered to contain specific antigens 
known to provide protection, have also been developed for Leptospira and are 
commercially available (Table 3). Historically Leptospira vaccines have been restricted 
to use in animals due to their high likelihood of causing adverse reactions 
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(reactogenicity) in humans (Adler and de la Pena Moctezuma, 2010). This 
reactogenicity of Leptospira vaccines has been associated with the presence of serum in 
the growth media (Koizumi and Watanabe, 2005); however vaccines derived from 
protein free media (Christopher et al., 1982) have not been shown to statistically 
decrease vaccine-associated side effects (Koizumi and Watanabe, 2005). Despite this, 
some human Leptospira vaccines have been successfully developed (Rodriguez-
Gonzalez et al., 2004, Koizumi and Watanabe, 2005), although they are not currently in 
widespread usage. Unfortunately, all the vaccines currently available only provide 
immunity to specific serovars (Koizumi and Watanabe, 2005) and require regular 
boosters (Klaasen et al., 2003). 
 
A number of other vaccines, such as recombinant outer membrane protein, recombinant 
lipoprotein, recombinant vector, LPS and DNA vaccines, have also been developed 
(Wang et al., 2007). A key problem associated with their development is a lack of 
information, both about Leptospiras route of infection and virulence factors. The 
majority of active research appears to concentrate on the development of subunit 
vaccines (Felix et al., 2011, Umamaheswari et al., 2012); however some success has 
also been reported in the creation of live attenuated LPS (Srikram et al., 2011) vaccines. 
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Table 3: Table of commercially available Leptospira vaccines available worldwide  
Manufacturer 
Commercial 
Name Formulation 
Target 
Species 
Immunises 
against Serovars 
Route(s) of 
Administration 
Wyeth (Fort 
Dodge) 
Triangle + 
Type II BVD Killed Bacteria Cattle 
Canicola, 
Grippotyphosa, 
Hardjo, 
Icterohaemorrhagiae, 
and Pomona 
Intramuscular 
Subcutaneous 
 
Duramune 
Max 5 
Subunit 
purification of 
live bacteria Dog 
Canicola, 
Grippotyphosa, 
Icterohaemorrhagiae 
and Pomona Subcutaneous 
 LeptoVax 4 
Subunit 
purification of 
live bacteria Dog 
Canicola, 
Grippotyphosa, 
Icterohaemorrhagiae 
and Pomona Subcutaneous 
 Kavak L 
Inactivated 
Bacteria Dog Data not available 
Intramuscular 
Subcutaneous 
Novartis Lepto Shield 5 
Inactivated 
Bacteria 
Cattle, 
Swine 
Canicola, 
Grippotyphosa, 
Hardjo, 
Icterohaemorrhagiae, 
and Pomona Intramuscular 
Pfizer Lepto-Eryvac 
Inactivated 
Bacteria Swine 
Pomona and 
Tarassovi Subcutaneous 
 Spirovac 
Inactivated 
Bacteria Cattle Hardjo Subcutaneous 
 Leptoferm-5 
Inactivated 
Bacteria Cattle 
Canicola, 
Grippotyphosa, 
Hardjo, 
Icterohaemorrhagiae, 
and Pomona Intramuscular 
 Leptoshield 
Data not 
available 
Cattle, 
Sheep, 
Goats, Deer Hardjo and Pomona Subcutaneous 
 
Vanguard 
Lepto ci 
Inactivated 
Bacteria Dogs Data not available 
Intramuscular 
Subcutaneous 
 Ultravac 
Data not 
available Cattle Hardjo and Pomona Subcutaneous 
Schering-Plough Leptavoid 2 
Inactivated 
Bacteria 
Cattle, 
Sheep, Pigs, 
Deer Hardjo and Pomona Subcutaneous 
 Leptavoid 3 
Inactivated 
Bacteria Cattle, Deer 
Pomona, Hardjo and 
Icterohaemorrhagiae Subcutaneous 
Intervet 
Nobivac Lepto 
2 
Inactivated 
Bacteria Dog 
Icterohaemorrhagiae 
and Canicola Subcutaneous 
 VL5 SQ 
Inactivated 
Bacteria Cattle 
Canicola, 
Grippotyphosa, 
Hardjo, 
Icterohaemorrhagiae, 
and Pomona Subcutaneous 
 Procyon 
Inactivated 
Bacteria Dog 
Icterohaemorrhagiae 
and Canicola 
Intramuscular 
Subcutaneous 
Virbac Lepto 2 way 
Inactivated 
Bacteria Cattle Hardjo and Pomona Subcutaneous 
 Lepto 3 way 
Inactivated 
Bacteria Cattle 
Hardjo, Pomona and 
Copenhageni Subcutaneous 
 
Canigen Lepto 
2 
Inactivated 
Bacteria Dog 
Canicola and 
Icterohaemorrhagiae Subcutaneous 
Merial Eurican L 
Inactivated 
Bacteria Dog 
Canicola and 
Icterohaemorrhagiae 
Intramuscular 
Subcutaneous 
Agvax Trilepto 
Inactivated 
Bacteria Cattle Hardjo and Pomona Subcutaneous 
Note: whilst this table is comprehensive it is not exhaustive and should not be taken as such.
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1.4 Leptospira vaccine batch potency testing 
The current Leptospira vaccine batch potency test used for serovar Canicola dog 
vaccines has been identified as severe, and in need of replacement, by the royal society 
for the prevention of cruelty to animals (RSPCA) (Cooper and Jennings, 2008) as it 
involves a high number of animal deaths following challenge from live organisms 
which produces a corresponding high degree of suffering (as euthanasia is not typically 
used to avoid skewing the results). In addition, the serovar Canicola strain used in the 
test must be regularly passed through hamsters (passaged), to prevent any loss of 
virulence associated with in vitro culture (Haake et al., 1991), resulting in further 
suffering and loss of life. Furthermore the test is time consuming, expensive and puts 
personnel at risk of exposure to an ACDP (advisory committee on dangerous 
pathogens) hazard group II organism. 
 
The current requirements for assessing the potency of serovar Canicola vaccines, as laid 
out in the most recent European monograph (1997), specifies the use of 10 hamsters no 
more than three months old and from the same stock. Five of the hamsters are 
inoculated with the vaccine (at a 40 times dilution) by subcutaneous injection, the other 
five act as a control group and are unvaccinated. Fifteen to twenty days following 
vaccination all 10 hamsters are challenged by inoculation with a virulent strain of 
serovar Canicola intraperitoneally. 
 
The vaccine is considered appropriately potent if a minimum of 4 hamsters from the 
control group die within 14 days of infection (precise dosage of the bacteria varies 
depending on the strain virulence) and if a minimum of 4 hamsters from the vaccinated 
group are healthy 14 days after the death of the control animals. Although this test is 
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established to be effective the use of 5 hamsters per group is not statistically ideal. A 
power analysis would enable an optimal sample size to be derived; however any 
statistical benefits resulting from increasing the number of animals used per group 
would have to be carefully considered by the European pharmacopoeia prior to 
implementation. 
 
1.4.1 In vitro alternatives to animal testing 
Various monoclonal antibody based ELISA techniques have been developed to both 
assess potency and quantify specific Leptospiral antigens in vaccines. Whilst this has 
been successful for some serovars, such as Pomona (Ruby et al., 1992), similar attempts 
using serovar Canicola have had mixed success (Ebert, 1999); possibly due to the effect 
of adjuvant variation between batches. ELISA potency tests for certain specific serovar 
Canicola vaccines have been developed in the USA (Ruby et al., 1996); however, these 
require that adjuvants be removed from the vaccines prior to testing which is not 
practical for widespread implementation due to the wide variety of adjuvants used by 
different manufacturers. It has been clearly established however (Guerreiro et al., 2001, 
Ruby, 1999) that both protein and lipopolysaccharide (LPS), derived from Leptospira, 
are capable of eliciting an immune response. 
 
Use of the MAT as an alternative to the hamster challenge test was first proposed in 
1986 (Goddard et al., 1986). A subsequent study (Ebert, 1999), using Leptospira 
borgpetersenii serovar Hardjo vaccines and guinea pig serum substantiated Goddard et 
al’s results. However, this line of research has seemingly been abandoned in favour of 
true in vitro alternatives (such as the ELISA). This may be due to the fact that the MAT, 
although requiring lesser numbers than the hamster challenge test, still involves animal 
infection (to obtain the serum). 
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1.4.2 Current Situation 
As noted in the recent RSPCA report (Cooper and Jennings, 2008) the existing in vitro 
methods outlined above have largely not been put into widespread usage; primarily due 
to the effects of adjuvant interference with ELISA based techniques (Personal 
communication). Current work in this area focuses predominantly on the improvement 
of the existing in vivo test (Stokes et al., 2011), rather than the development of novel 
approaches for determining vaccine potency in vitro. 
 
1.5 Principles and Applications of Proteomics 
1.5.1 Protein characterisation of Vaccines 
Many vaccines currently available, particularly those derived from heat/chemically 
killed bacteria, lack a defined mechanism for their ability to confer protective immunity; 
which hinders the development of specific in vitro potency tests and the design of more 
efficacious vaccines. Mass spectrometry based analysis of immune proteins (termed 
immunoproteomics) can often be utilised to characterise the immune response to foreign 
organisms (Purcell and Gorman, 2004); however proteomic analysis of vaccines is not 
widely used and the characterisation of Leptospira vaccines has not been previously 
reported. 
 
The majority of research to date has concentrated on the proteomic identification of 
novel vaccine candidates. Proteomic ‘vaccine’ analysis has also been reported (Tsolakos 
et al., 2010), although this generally concentrates on characterising the bacterial strain 
used to manufacture the vaccine (Uli et al., 2006), rather than the final vaccine 
preparation (containing adjuvant and preservative) released for commercial sale. 
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Despite this, gel based mass spectrometry techniques for vaccine characterisation have 
been developed (Hennessey et al., 1999, Vipond et al., 2005) and a method for the 
desorption of aluminium phosphate adjuvant from anthrax vaccines has also been 
described (Whiting et al., 2004). In addition mass spectrometry based analysis of 
peptide vaccines has been reported for the purposes of quality control (Metz et al., 
2002). 
 
1.5.2 Sample Preparation 
The majority of proteomic techniques require that the sample of interest be prepared 
prior to analysis to optimise downstream separation and mass analysis. Preparation 
methods can vary depending on the sample and the separation/analysis techniques used 
and are usually independently validated for each study. However, in general, sample 
preparation aims to increase the solubility of proteins (often through the use of 
denaturing agents) whilst reducing contamination (such as salts, highly abundant 
proteins etc) which could affect downstream analysis. Common techniques used include 
solid (Callesen et al., 2009) and liquid (Peng et al., 2001) phase extraction, protein 
precipitation (Fic et al., 2010) and molecular weight filtration (Greening and Simpson, 
2010). 
 
1.5.3 Protein separation 
Separation of complex protein samples is usually required for identification and 
isolation of proteins of interest. Proteins can be separated out by their charge, size, 
isoelectric point and/or hydrophobicity depending on the precise needs of the 
experiment; common analytical separation techniques include gel electrophoresis, 
isoelectric focusing and chromatography. Separation is often done in conjunction with 
mass spectrometry which usually requires the use of proteolytic enzymes (for example 
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trypsin, chymotrypsin and proteinase K) either prior to separation when using liquid 
chromatography or after separation when using gel electrophoresis (often referred to as 
‘in gel digestion’(Weeks, 2010)). Complete enzymatic digestion of the samples can be 
impeded by the presence of contaminants and/or the incorrect pH making sample 
preparation (section 1.5.2) vitally important; in addition, samples have to be heat and/or 
chemically denatured prior to the addition of the proteolytic enzyme to break down the 
tertiary and quaternary structure of the protein, allowing the enzyme access to its 
cleavage site (lysine and arginine residues in the case of trypsin). 
 
Gel based protein separation is achieved by performing sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE). In brief the sample is mixed with a 
loading buffer, containing dye and SDS, and heat denatured causing the proteins to 
become charged. An electric field is then applied to the gel whereby the charged 
proteins will travel through the gel, with smaller proteins migrating quicker as they can 
fit through the pores of the gel easier, thus allowing a complex protein mixture to be 
separated out by size; a protein ladder comprising of known molecular weights is often 
run alongside samples to allow direct estimation of sample size. A variation of this is 
2D-PAGE (Issaq and Veenstra, 2008) which allows further resolution of the protein 
sample by separating the samples based on their isoelectric point prior to SDS-PAGE. 
Western blotting can be used in conjunction with SDS-PAGE and 2D-PAGE allowing 
the identification of proteins based on their reactivity to antibodies (Burnette, 1981). For 
identification protein ‘spots’ separated by electrophoresis can be excised from the gel 
and then analysed using mass spectrometry (Weeks, 2010). However, whilst this is a 
valid and useful strategy it requires a large amount of sample handling, introducing the 
potential for sample loss (Staudenmann et al., 1998); additionally, it cannot effectively 
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separate certain proteins, such as those that are strongly alkaline/hydrophobic and/or 
membrane proteins (Beranova-Giorgianni, 2003). 
 
Liquid chromatography is an alternative to gel based separation methods which involves 
allowing the samples to interact with a stationary phase (contained within a column) and 
then elution by passing an appropriate mobile phase over the stationary phase at a high 
pressure. The use of smaller particle sizes in the stationary phase can increase the 
resolution (Novakova et al., 2006), i.e. the ability to distinguish between peaks, of the 
separation. However, a higher flow pressure through the column is also then required 
(due to the Van Deemter equation) this is commonly referred to as ultra-high pressure 
chromatography (UHPLC).  Multiple combinations of stationary and mobile phases can 
be used according to which chemical property the sample of interest is to be separated 
out by. A common example of liquid chromatography separation is reverse phase high 
pressure liquid chromatography (RP-HPLC), which separates molecules based on their 
hydrophobicity (through interaction with a non-polar stationary phase and polar mobile 
phase). Ion exchange chromatography is also routinely used whereby the stationary 
phase is either negatively (cation exchange) or positively (anion exchange) charged and 
the mobile phase is the reverse; mixed bed columns are also available (Motoyama et al., 
2007) which retain both anions and cations. Another common option is size exclusion 
chromatography which uses a non-reactive stationary phase containing different sized 
pores; smaller molecules in the sample pass through the pores which retards their 
progress, whereas larger molecules do not and therefore elute from the column earlier. 
An affective combination for maximising protein separation utilises strong cation 
exchange in conjunction with RP-HPLC, which is often performed prior to mass 
spectrometry (Coldham and Woodward, 2004). 
 
 42 
1.5.4 Mass Spectrometry 
Following chromatographic or electrophoretic separation of the sample, it has to be 
ionised prior to entering into the mass spectrometer, typically either through 
electrospray ionisation (ESI) or atmospheric pressure chemical ionisation (APCI). This 
approach of enzymatically digesting proteins prior to separation and analysis on a mass 
spectrometer is commonly referred as a ‘bottom up’ approach. A popular alternative to 
this is termed ‘top down’ proteomics which has no protein digestion allowing intact 
proteins to be analysed on the mass spectrometer. These top down approaches can 
provide better overall protein coverage however they cannot achieve the separation and 
sensitivity of bottom up proteomics (Yates et al., 2009). Tandem mass spectrometers 
(de Hoffman and Stroobant, 2007) are arguably amongst the more widespread 
instruments used for both quantitative and shotgun based proteomics. Although hybrid 
mass spectrometers using ion traps in conjunction with an orbitrap (Kalli and Hess, 
2012) are increasingly being used in place of Q-ToF based apparatus (Table 4).  
 
After analysis the resultant mass spectra data can then be interrogated against a protein 
database (generally predicted from the genome for the organism of interest), using a 
suitable search program, to determine the protein content of the analysed sample. Search 
programs can be set to take into account known post translational modifications to 
ensure accuracy of identifications.  
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Table 4: Advantages and disadvantages of different types of mass spectrometer 
Mass Spectrometer Description Advantage Disadvantage 
QQQ 
 
Comprised of 3 quadrupoles for 
filtering/fragmenting ions 
 
 
Highly sensitive quadrupoles 
can be used to select known 
product/precursor ions enabling 
accurate quantitation of peptides 
Prior knowledge of 
product/precursor ions 
and collision energies 
is required. 
Q-ToF 
As QQQ with the addition of 
a time of flight tube for accurate 
mass detection 
Allows for the identification of 
previously unknown proteins/peptides 
and their product/precursor ions 
Limited number of 
uses compared 
to modern orbitraps 
Linear ion trap (LIT) Orbitrap 
LIT can be used to store, 
isolate and/or fragment ions 
independently or in conjunction 
with the Orbitrap analyser 
Greater mass accuracy and sensitivity 
than Q-ToF resulting in more 
identifications 
 
Not as accurate as 
QQQ for small 
molecule quantitation. 
Expensive 
 
 44 
1.5.5 Protein quantitation 
Quantitation of protein concentrations within samples is vitally important for the 
interpretation of proteomic datasets into usable biological observations. Existing 
approaches for quantitation can be broadly categorised as either being labelled or label 
free; each method has its disadvantages which should be carefully considered when 
planning experiments (Table 5). 
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Table 5: Comparison of different quantitation techniques used in mass spectrometry 
Technique Description Advantage Disadvantage 
Stable isotope 
labelling with 
amino acids in 
cell culture 
(SILAC) 
 
 
Measures relative 
proteomic 
differences in 
metabolism using 
labelled amino 
acids in the 
growth media 
Excellent 
labelling 
efficiency 
leading to 
good protein 
coverage 
 
Limited to cell 
culture experiments 
 
 
 
 
 
Isotope coded 
affinity tags 
(ICAT) 
 
Utilises a thiol 
specific affinity 
tag for protein 
quantitation 
Rapid 
 
 
Non- cysteine 
peptides residues 
not detected. 
 
Tandem mass 
tags (TMT) 
 
 
 
 
 
Mass tags 
attached to 
peptides allowing 
determination of 
the relative 
abundance of 
proteins 
Allows for the 
quantitation & 
comparison of 
proteins in up 
to 6 different 
groups in 1 
experiment 
Underestimation of 
abundance 
 
 
 
 
 
Isobaric tags for 
relative & 
absolute 
quantitation 
(iTRAQ) 
As TMT however 
up to 8 channels 
can be labelled 
 
 
As TMT but 
can compare 
up to 8 
different 
groups 
As TMT 
 
 
 
 
Absolute 
quantification of 
proteins 
(AQUA) 
Uses a labelled 
internal standard 
for quantification 
 
Highly 
accurate 
 
 
Expensive. 
Can only quantitate 
known proteins/peptides 
 
Spectral 
counting 
 
 
 
Equates the 
number of 
detected spectra 
for a protein to its 
abundance 
Low cost per 
sample. Rapid 
 
 
 
Results can be skewed 
due to the inability 
of 2D-LC/MS to 
detect all of a proteins 
constituent peptides 
Absolute 
protein 
expression 
measurements 
(APEX) 
 
 
Variation of 
spectral counting 
which uses 
machine learning 
to adjust the 
relative spectral 
abundance 
As spectral 
counting 
 
 
 
 
 
As spectral counting 
 
 
 
 
 
 
LC-MSe 
 
 
 
Equates signal 
intensity with 
peptide/protein 
abundance 
Low cost per 
sample. Rapid 
 
 
Reliant on the accuracy 
and reproducibility 
of the liquid 
chromatography 
Single/multiple 
reaction 
monitoring 
(SRM/MRM) 
 
 
Compares the 
abundance of the 
sample against a 
calibration curve 
of a synthetic 
peptide 
Highly 
accurate 
 
 
 
 
Can only quantitate 
known proteins/peptides 
 
 
 
 
 46 
1.6 Aims and Objectives  
The hypothesis of this study is that one or more protein/LPS potency biomarkers can be 
identified in commercially available Leptospira interrogans serovar Canicola vaccines 
and that these biomarkers may be used to replace the existing hamster challenge 
potency test. The primary objective of this study is the identification of protein and/or 
LPS potency biomarker(s) which may be suitable for the development of an in vitro 
vaccine batch potency test, to differentiate between efficacious and non- efficacious 
batches of serovar Canicola vaccine. The secondary objective of this study is to provide 
proof of principle of the feasibility for such an in vitro potency test using the potency 
biomarker(s) identified herein. 
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Chapter 2  Materials and Methods 
2.1 Statistical Analysis 
All results are presented as means and standard deviations of the mean; with the 
exception of proteomics data where proteins not common to all three replicates have 
been excluded from analysis. Comparison of the concentration and relative abundance 
of proteins between vaccines was performed using a Student’s t-test; a P value of ≤0.05 
was taken to be statistically significant. Comparison of the survival of hamster groups 
1-6 was performed using Fisher’s exact test; a P value of ≤0.05 was taken to be 
statistically significant. The limit of detection (LOD) was calculated (Armbruster and 
Pry, 2008) as LOD = LOB + 1.645(SD lowest concentration sample), where LOB = mean blank + 
1.645(SD blank). Whereas the limit of quantification (LOQ) was defined as the lowest 
concentration of the standard with a coefficient of variation lower than 20% 
(Armbruster and Pry, 2008).  
 
2.2 Ethical approval 
All animal procedures in this study were covered under the Animals (Scientific 
Procedures) Act 1986 by Home Office Project Licence No. PPL 70/7249 and were 
approved by the Animal Ethics Committee at the Animal Health and Veterinary 
Laboratories Agency (AHVLA) where all of this work was performed.  
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2.3 Bacterial Methodology 
2.3.1 Bacterial strains 
Leptospira interrogans serovar Canicola strain Hond Utrecht IV was obtained from the 
Animal Health and Veterinary Laboratories Agency (AHVLA; UK). L. interrogans 
serovar Canicola strain Kito was donated by the Pasteur Institute (France). Escherichia 
coli chemically competent cells, strain BL21(DE3) pLysS, were obtained from Promega 
(Southampton, UK). 
 
2.3.2 Bacterial culture 
Starter cultures of L. interrogans serovar Canicola (strains Hond Utrecht IV and Kito) 
were prepared by inoculation of Ellinghausen McCullough Johnson Harris (EMJH) 
media (20 ml; Becton Dickinson, USA) with 1 ml of pure culture (1 x 108 cell/ml) and 
incubated for 7 days at 30o C with orbital agitation at 50 rpm. Larger working cultures 
(n=3) of strain Hond Utrecht IV for proteome extraction were initiated by inoculation of  
EMJH media (400 ml) with starter culture (10 ml) and incubated at 30o C with orbital 
agitation at 50 rpm for 7 days.  
 
The recombinant LipL32 E. coli strain (section 2.6.4) was grown on Luria-Bertani (LB) 
agar plates (35 µg/ml chloramphenicol and 50 µg/ml ampicillin) at 37o C overnight to 
screen for transformant colonies. For expression of LipL32 protein the recombinant E. 
coli strain was grown to an optical density (OD600) of 0.4 at 37o C with orbital agitation 
at 225 rpm in LB broth (500 ml) containing 35 µg/ml chloramphenicol and 50 µg/ml 
ampicillin; isopropyl β-D-1-thiogalactopyranoside (IPTG) was added, to a final 
concentration of 2 mM to induce LipL32 expression and cultures were incubated for a 
further 4 hours before harvesting of bacterial cells (section 2.6.5). 
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2.3.3 Assessment of Bacterial Growth 
The growth of L. interrogans serovar Canicola (strains Hond Utrecht IV and Kito) were 
assessed by counting cells with a dark field microscopy using a Thoma counting 
chamber (0.1 mm depth, 1/400 m2). The growth of E. coli strains, for expression of 
recombinant LipL32, was assessed using a Spectronic Unicam Helios Gamma 
spectrophotometer (ThermoFisher, USA) at an OD of 600 nm. 
 
2.3.4 Serotyping of Leptospira interrogans 
L. interrogans serovar Canicola (strains Hond Utrecht IV and Kito) were serotyped 
using the MAT prior to use to confirm their serovars. Serovar Canicola specific 
antiserum (AHVLA, UK) was serially diluted (1/25 to 1/3200) in 0.9% (w/v) 
physiological saline to a final volume of 25 µl and added (in duplicate) to the wells of a 
flat bottomed 96 well plate (Nunc, UK). Aliquots (25 µl) of strains Hond Utrecht IV and 
Kito, grown to ~5 x 108 cells/ml, were then passed through a 0.8 µm filter syringe (to 
remove any bacterial aggregates that may have formed which might skew results) and 
added to the diluted antisera; known L. interrogans serovar Canicola and serovar 
Copenhageni strains were used as positive and negative controls respectively. The 96 
well plates were incubated at 30o C for 2 hours and wells were then assessed for 
agglutination using a dark field microscope at 40 times magnification. 
 
2.3.5 Bacterial Protein Extraction for 2D-LC/MSn Analysis 
L. interrogans serovar Canicola (strain Hond Utrecht IV), cultured as previously 
described (section 2.3.2), was harvested during the logarithmic growth phase (~5 x 108 
cells/ml). Cultures were cooled on ice for 30 minutes prior to centrifugation using a 
Sorvall RC 6 plus centrifuge (ThermoFisher, UK) at 4000 x g for 20 minutes at 4o C. 
The bacterial cells were washed by suspension in chilled phosphate buffered saline (100 
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ml; PBS; 200 mM, pH 7.2) and centrifuged (4000 x g; 20 min, 4o C). Bacterial cell 
pellets were suspended in chilled PBS (10 ml) containing PMSF (100 µM) and lysed by 
6 second pulses of probe sonication (amplitude 60) using a Vibra-Cell ultrasonic 
processor (Sonics and Materials, USA) for 3 minutes on ice. Cell debris was removed 
by centrifugation at 3000 x g and the supernatant retained. A cytosolic extract was 
produced from the supernatant by centrifugation at 32000 x g for 30 minutes. The pellet 
was retained and the supernatant (cytosol extract) was diluted by the addition of 2.5 mM 
ammonium bicarbonate (2 ml; pH 8.0) and centrifuged in 5 kDa molecular weight cut 
off filters (MWCO; Sartorius Stedim, France) to desalt and concentrate to a final 
volume of 0.5 ml; this was stored at -20o C. 
 
The retained pellet was then washed by suspension in chilled PBS (200 mM, pH 7.2) 
and collected by centrifugation (32000 x g). The washed pellet was re-dissolved in lysis 
buffer (3 ml; Urea 5 M, Thiourea 2 M, DTT 100 mM, CHAPS 2% (w/v), 3-
(Decyldimethylammonio) propanesulfonate inner salt 2% (w/v), Tris Base 0.48% (w/v)) 
and centrifuged at 32000 x g for 30 minutes. The protein extract was precipitated in a 4-
fold excess of ice cold acetone and incubated at -20o C for 48 hours prior to 
centrifugation (3000 x g for 30 minutes at 4o C). The resulting pellet (precipitated 
extract) was desalted and concentrated as described above to remove excess acetone. 
 
2.3.6 Standard Protein Assay  
The protein concentration of all samples (unless otherwise stated) was determined using 
the Bradford method (Bradford, 1976). Vaccines A-E (before and after MWCO 
washing) and the bacterial extracts were determined by Bradford. Essentially samples 
were diluted 1/20 and 1/100, with 2.5 mM Ammonium bicarbonate (pH 8.0), in 
duplicate to a final volume of 1 ml; a range of protein calibration standards (1- 0.05 
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mg/ml) were also created in duplicate using bovine serum albumin (BSA; Sigma, UK) 
diluted with 2.5 mM Ammonium bicarbonate (pH 8.0). Aliquots (100 µl) of diluted 
sample and protein standards were added in duplicate to Bradford reagent (2 ml; Sigma, 
UK), briefly vortexed and left to incubate in the dark at room temperature for 30 
minutes. Protein concentration was assessed using a Spectronic Unicam Helios Gamma 
spectrophotometer (ThermoFisher, USA) at an optical density (OD) of 600 nm. 
Calibration curves for the BSA standards were constructed using Graphpad Prism 4 
software (Graphpad, USA) over the tested concentration range (1- 0.05 mg/ml) allowing 
determination of sample concentration by interpolation.  
 
2.3.7 Low concentration Protein Assay 
Due to the low sample volume obtained from recombinant cells the protein content of 
purified LipL32 protein (section 2.6.5) was determined using a Nanodrop ND-1000 
(Thermo Scientific, UK). 
 
2.4 Vaccine Methodology 
2.4.1 Vaccines 
Bivalent vaccines (giving protection against serovars Canicola and 
Icterohaemorrhagiae) which had passed the in vivo vaccine batch potency test and had 
been released for commercial sale were purchased from six different manufacturers 
(designated A-F) for analysis. Vaccine C was of subunit manufacture comprising outer 
membrane proteins whereas vaccines A, B, D, E and F were derived from heat 
inactivated bacteria. Untested batches of vaccine C (n=5) were obtained from the 
manufacturer and assessed during this study for their protective effect using the vaccine 
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batch potency test; untested batches of vaccines A, B, D, E and F were unavailable for 
testing.   
 
2.4.2 Vaccine batch potency testing 
Untested batches (n=5) of vaccine C were assessed for potency according to the 
guidelines laid out in the most recent European monograph (Marbehant, 1999). For each 
batch analysed five female hamsters (≤120 g; Charles River, Germany) were inoculated 
subcutaneously with 0.5 ml of vaccine (diluted 1/40 with 0.9% w/v physiological 
saline), five unvaccinated hamsters were kept as control animals. Fifteen days following 
vaccination all the hamsters were challenged by intraperitoneal inoculation with 1 ml of 
virulent Leptospira interrogans serovar Canicola (~1 x 108 cells/ml) strain Kito. For the 
test to be valid at least four of the five unvaccinated controls had to succumb to 
infection or be euthanased (according to a clinical score sheet, Table 6) within 14 days 
of infection. Vaccine batches were deemed potent if at least four of the five vaccinated 
hamsters survived for 14 days longer than the unvaccinated controls. Hamsters were 
routinely monitored and their condition assessed using a clinical score sheet (Table 6) 
developed at AHVLA. Hamsters with a score of 3 or higher were humanely euthanased 
using halothane; all surviving hamsters at the end of the test were also humanely 
euthanased. 
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Table 6: Clinical Score sheet used to assess condition of hamsters 
Clinical Signs Score Action 
Normal behaviour 0 None required 
Arched back with slightly rough coat 1 Observe again in 2 hours. 
Dull sunken eyes Observe again in 2 hours. 
Moderately rough coat If symptoms at the end of the day, 
Subdued but will respond when 
stimulated 
2 
consult the Named Veterinary Surgeon (and study director if 
possible) 
Unstable on feet 
Subdued, will not respond when 
stimulated 
Nasal bleeding 
Blood in urine 
3 Euthanise (= killed in extremis) 
Prostration 
Permanently closed eyes 4 Euthanise (= killed moribund) 
Found dead 5 None required 
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2.4.3 Quantitation of LPS  
Limulus amebocyte lysate (LAL) assay was performed using an Endochrome K kit 
(Charles River, UK) according to the manufacturer’s instructions. The concentration of 
LPS in unknown samples was determined by interpolation, using Graphpad Prism 4 
software (Graphpad, USA), against a calibration curve (0.33-3333 ng/ml) prepared from 
LPS (E. coli derived; Charles River, UK). 
 
2.4.4 Protein and LPS Gel Electrophoresis 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was 
performed on X cell surelock system (Invitrogen, USA) using precast 4-12% gradient 
NuPAGE gels (Invitrogen, USA) run at 150 W for 80 minutes. For assessment of the 
protein and LPS content present in the vaccines, gels contained a 3.5- 260 kDa protein 
ladder (Invitrogen, USA), two concentrations of E. coli derived LPS (10 µg and 500 ng; 
Sigma, UK) and aliquots of untreated vaccine (A-E). Protein was visualised in gels by 
staining with EZ run Coomassie (Thermo Fisher, USA) used according to the 
manufacturer’s instructions. LPS was detected in the gels using the silver staining 
method described by Tsai (Tsai and Frasch, 1982). For validation that the silver stain 
method was specific to LPS, vaccines A-E (72 µl) were also digested with 16 µg 
proteinase K (to digest the protein content; resuspended in 500 mM Tris HCl, 50 mM 
CaCl2, pH 7.5) at 37o C overnight. The vaccine digests A-E were equally divided (2 x 
36 µl), one aliquot was loaded onto a gel stained with the silver stain and the other 
aliquot was loaded onto a gel stained with EZ run Coomassie to confirm that complete 
digestion had taken place. 
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2.4.5 Vaccine preparation for 2D-LC/MSn Analysis 
Vaccines A, C, D and E (1 ml) were concentrated to 0.5 ml using 5 kDa molecular 
weight cut off filters (MWCO; Sartorius Stedim, France), washed once with 2.5 mM 
ammonium bicarbonate (2 ml; pH 8.0) and concentrated again to a final volume of 0.5 
ml. Due to a low initial protein content the concentration of vaccine B could not be 
accurately determined after washing, therefore unprocessed unwashed vaccine was 
subjected to direct trypsin digestion and subsequent 2D-LC/MSn analysis. 
 
2.5 Proteomic Analysis of Bacteria and Vaccines 
2.5.1 Trypsin digestion of proteins 
Three replicates of each vaccine and bacterial extract, normalised by dilution in 2.5 mM 
ammonium bicarbonate (pH 8.0) to 100 µg, were heat denatured at 95o C for 5 minutes 
and then digested overnight with 2 µg sequencing grade trypsin (Promega, 
Southampton) (Coldham and Woodward, 2004). Digestion was terminated by the 
addition of 25.2 M formic acid (1 µl; Fluka, USA). Due to the low protein content of 
vaccine B, 6 µg of protein was used for each replicate. 
 
2.5.2 Proteome analysis by 2D-LC/MSn 
Tryptic digests were centrifuged (5000 x g for 1 minute) to remove particulates and 50 
µl aliquots of supernatant was subjected to strong cation exchange (SCX) fractionation 
by high pressure liquid chromatography (HPLC). Tryptic peptides were fractionated on 
a Biobasic SCX HPLC (2.1 x 100 mm) column (Thermo Scientific, UK) using a 
Hewlett-Packard 1100 HPLC system at a flow rate of 0.25 ml/min. Mobile phases used 
were 75:25 2.5 mM ammonium acetate: acetonitrile pH 4.5 (A) and 75:25 250 mM 
ammonium acetate: acetonitrile pH 4.5 (B) with a binary gradient (t = 0 min, A 100%; t 
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= 5 min, A 100%; t = 18 min, 65% A; t = 20 min, B 100%; t = 22 min, A 100%; t = 32 
min, A 100%). Eluted peptides were monitored at 280 nm and 15 fractions (0.25 ml) 
were collected between 8 and 23 min. The SCX fractions were taken to dryness at 60o C 
under vacuum using an Eppendorf 5301 centrifugal concentrator (Eppendorf, UK). 
Dried SCX fractions were resuspended in 0.1% v/v formic acid (20 µl) and analyzed on 
an Agilent 6520 Quadrupole Time-of-Flight (Q-TOF) mass spectrometer (Agilent 
Technologies, UK) with an HPLC chip cube source. The chip consisted of a 40 nl 
enrichment column (Zorbax 300 SB- C18; 5 µm) and a 75 µm x 150 mm analytical 
column (Zorbax 300 SB- C18; 5 µm) driven by the Agilent Technologies 1200 series 
nano/capillary HPLC system. Both pumps (nano and capillary) were controlled by 
Masshunter Workstation Data Acquisition for Q-TOF (Version B.02.00, Patches 1, 2; 
Agilent Technologies). Tryptic peptides (1 µl injection volume) were loaded onto the 
enrichment column of the chip and washed with eight column volumes of 0.1% v/v 
Trifluoroacetic acid (TFA). Tryptic peptides were separated on the analytical column 
and eluted directly into the mass spectrometer. Mobile phases used were 0.1% v/v TFA 
(A) and 90:10 acetonitrile: 0.1% v/v FA (B) with a binary gradient (t = 0 min, A 95%; t 
= 5 min, A 95%; t = 40 min, A 60%; t = 41 min, A 20%; t = 45 min, A 20%; t = 47 min, 
A 95%) at a flow rate of 0.6 µl/min. The mass spectrometer was run in positive ion 
mode, and MS survey scans were run over a range of m/z 250 to 3000 and at five 
spectra per second. Precursor ions were selected for auto MS/MS at an absolute 
intensity threshold of 2000 and a relative threshold of 0.01, with a maximum of 5 
precursors per cycle, and active exclusion set at 1 spectra and released after 3 minutes. 
Precursor charge state selection and preference were set to 2+ and then 3+. The mass 
spectrometer was calibrated to within a residual error of 2 ppm prior to each batch using 
ES-TOF Tuning Mix (Agilent, UK). A synthetic peptide mix (10 ng/ml; MRFA, 
AVDQLNEQSSEPNIYR, VTALYEGFTVQNEANK, ARPQELPFLASIQNQGR, 
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ISVNNVLPVDFNLMQQK and NYINQYSEVAIQMVMHMQPK) was analysed prior 
to each batch (defined as 15 SCX fractions) for quality assurance of both 
chromatography and mass spectrometry. The m/z values of the tuning mix calibrants 
were added to an exclusion list to ensure only sample derived peptides were 
subsequently analysed in full MS/MS mode. Two blank samples (comprising of 0.1% 
formic acid and 95:5% acetonitrile: H2O) were analysed at the end of each batch to 
normalise and flush the column and system prior to subsequent analytical injections. 
 
Initial data for vaccine proteome analysis showed high albumin concentration, therefore 
the most abundant albumin precursor ions were excluded from further analysis by 
creating a specific precursor ion exclusion list method (ions specified were not 
analysed). 
 
2.5.3 Proteome analysis by 1D PAGE-LC/MSn 
In-gel trypsin digestion of vaccine samples was carried out according to the method 
described by Weeks (2010); LC/MSn mass analysis was performed as previously 
described (section 2.5.2) using an Agilent 6520 Q-TOF. Mobile phases used were 0.1% 
v/v TFA (A) and 90:10 acetonitrile: 0.1% v/v FA (B) with a binary gradient (t = 0 min, 
A 96%; t = 15 min, A 50%; t = 16.5 min, A 10%; t = 18.5 min, A 95%; t = 21 min, A 
95%) at a flow rate of 0.6 µl/min.  
 
2.5.4 Protein identification  
The search engine Spectrum Mill (Agilent, UK) was used to extract MS/MS data from 
Masshunter acquisition files and proteins were subsequently identified by comparison 
of tryptic peptide product ion mass spectra against those generated in silico from a 
protein database. Search parameters included selection of trypsin as the proteolytic 
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enzyme with up to two missed cleavage sites and a variable modification for oxidation 
of methionine residues; precursor and product mass tolerances were set to 20 and 50 
ppm respectively. Identified protein lists (and associated information) with a Spectrum 
Mill protein score higher than 11 were exported as tab separated files for bioinformatic 
analysis; protein identifications were accepted if at least two distinct different tryptic 
peptides were present in all three technical replicates. To date Leptospira interrogans 
serovar Canicola has not been fully genome sequenced therefore a custom made 
database derived from chromosomes I and II of L. interrogans serovar Copenhageni  
(ftp://ftp.ncbi.nlm.nih.gov/genomes/Bacteria/Leptospira_interrogans_serovar_Copenha
geni accessed on 12/6/10) was used for protein identification. To determine optimal 
database identifications vaccine D was also interrogated against the NCBI non-
redundant database (ftp://ftp.ncbi.nlm.nih.gov/blast/db/FASTA/nr.gz accessed on 
12/6/10), and the Uniprot database 
(ftp://ftp.uniprot.org/pub/databases/uniprot/knowledgebase/uniprot_sprot.fasta.gz 
accessed on 12/6/10) using Spectrum Mill (Agilent, UK). To determine the optimal 
search engine vaccine D was interrogated against the custom L. interrogans serovar 
Copenhageni database using the open mass spectrometry search algorithm (OMSSA; 
NCBI) and Mascot (Matrix Science). The false discovery rate (FDR) (Elias et al., 2005), 
defined as the percentage of false positive identifications, was calculated by searching 
the three replicates of vaccine D against a reverse decoy database, created from the L. 
interrogans serovar Copenhageni database using the Perl script decoy.pl available from 
(http://www.matrixscience.com/help/decoy_help.html accessed on 5/8/10). 
 
Access software (Microsoft Office 2003, USA) was used to identify proteins common 
to all technical repeats (n=3) for each sample, these common proteins are referred 
herein as a samples proteome; proteins not present in all three technical replicates were 
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discarded from further analysis. Conserved proteins in the precipitated and cytosol 
bacterial extracts were reassembled into a L. interrogans serovar Canicola proteome 
using Access (Microsoft Office 2003, USA). Comparison of the proteomes for vaccines 
A-E and serovar Canicola was also performed using Access (Microsoft Office 2003, 
USA). 
 
The relative abundance of proteins present in samples (in all three technical repeats) 
was determined through spectral counting (Zybailov et al., 2005). The normalised 
spectral abundance factor (NSAF; Figure 3) was utilised to account for differences in 
protein length, allowing comparison of protein abundance between samples. This 
requires (Figure 3) that for each protein (k), the number of detected spectra for that 
protein (SpC) be divided by that proteins predicted length in amino acids (Length); this 
figure is then further divided by the sum of SpC/L for all the detected proteins (N). For 
expediency the NSAF was calculated using a novel program, written in R, developed at 
AHVLA. 
 
(SpC/Length)k
Σ (SpC/Length)i
(NSAF)k = N
i=1
 
Figure 3: Equation used to determine the NSAF for a protein (k) from (Zybailov et al., 2007). 
Where SpC is the number of detected spectra that correspond to the protein and length is the 
number of predicted amino acids in the protein (translated from its gene sequence). 
 
2.5.5 Quantification of LipL32 using LC-MRM 
LipL32 was analysed by LC-MRM analysis with quantitation against synthetic peptides, 
corresponding to N and C terminal tryptic peptides found in this protein. LipL32 
synthetic peptides were obtained at a purity of 98% (Peptides Synthetics, UK) and used 
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to make a range of calibration standards (0.01-100 fmol/µl). Vaccines A-E were 
prepared, quantified, and digested as described previously (sections 2.4.5). 
Recombinant LipL32 protein (0.5 µg; section 2.6.5) was digested with trypsin (in 
triplicate); half of this digest (0.25 µg of total protein) was subjected to SCX separation. 
SCX separation was performed as described previously (section 2.5.2), to clean up the 
sample, however the 15 fractions of each replicate were recombined prior to being taken 
to dryness, dissolved in 0.1% v/v formic acid (50 µl) and analyzed on an Agilent 6410 
triple quadrupole mass spectrometer (Agilent, UK) with an HPLC chip cube source. 
The chromatography chip consisted of a 160-nl enrichment column (Zorbax 300 SB- 
C18; 5 µm) and a 75µm x 150 mm analytical column (Zorbax 300 SB- C18; 5 µm) 
driven by the Agilent Technologies 1200 series nano/capillary liquid chromatography 
system. Both pumps (nano and capillary) were controlled by Masshunter Workstation 
Data Acquisition for Triple Quadrupole (Version B.02.01; Agilent Technologies). 
Tryptic peptides (1 µl injection volume) were loaded onto the enrichment column of the 
chip and washed with eight column volumes of 0.1% v/v TFA. Peptides were then 
separated on the analytical column and eluted directly into the mass spectrometer. 
Mobile phases used were 0.1% v/v TFA (A) and 90:10 acetonitrile: 0.1% v/v FA (B) 
with a binary gradient (t = 0 min, A 95%; t = 1 min, A 95%; t = 16 min, A 60%; t = 20 
min, A 20%; t = 21 min, A 0%; t = 24 min, A 0%; t = 25 min, A 95%) at a flow rate of 
0.6 µl/min. The mass spectrometer was run in positive ion mode, with the electrospray 
voltage set to 1900 V and gas temperature at 300o C. Optimal transitions and conditions 
for the peptides of interest were obtained using the MS and MS/MS data from previous 
Q-ToF analysis of vaccine C. The acquired data was quantified using the calibration 
standards (0.01-100 fmol/µl) with Agilent Masshunter Quantitative Analysis software 
(Version B.03.01; Agilent Technologies). 
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2.5.6 Functional annotation of Leptospira Proteomes 
Functional annotation of proteins present in the proteomes of serovars Canicola, 
Copenhageni and Pomona was determined using the Protein Information Resource 
(PIR; http://pir.georgetown.edu accessed on 30/01/12). 
 
2.6 Cloning and expression of LipL32 
2.6.1 DNA extraction 
Genomic DNA from L. interrogans serovar Canicola strain Kito was extracted for 
sequencing (section 2.6.3) using the modified cetyltrimethylammonium bromide 
(CTAB) method described by Ausubel (Ausubel, 1994). Plasmid DNA from 
recombinant E. coli strains (section 2.6.4) was extracted using a QIAGEN plasmid mini 
kit as per the manufacturer’s instructions (Qiagen, UK). Estimation of DNA 
concentration of all samples was performed using a Nanodrop ND-1000 (Thermo 
Scientific, UK) at 260 nm. 
 
2.6.2 DNA Gel Electrophoresis 
Agarose gel electrophoresis was performed for the analysis of PCR products, 
restrictions digestions and to check DNA integrity/size using a 1% w/v TAE agarose gel 
at 70 V for 90 minutes using a 1 Kb ladder (Promega, UK) and 6 x loading dye 
(Promega, UK). Gels were soaked in 0.5 µg/ml ethidium bromide for 30 minutes, 
destained in water for 30 minutes, and then visualised under UV radiation using Gene 
Genius (Syngene, UK). 
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2.6.3 Sequencing 
Genomic DNA (15 ng) from L. interrogans strain Kito was amplified using polymerase 
chain reaction (PCR) with primers 1 and 2 (20 pmol; Sigma, UK; Table 7); which 
annealed approximately 1305.8 kilobase pairs upstream and downstream of the LipL32 
gene respectively to give a 2612.4 kilobase fragment which included the LipL32 gene. 
PCR was performed in a 50 µl total reaction volume containing 10 x buffer (5 µl; 
Clonetech, USA), 100 x deoxyribonucleotides (0.5 µl; dNTPs; Promega, UK) and taq 
polymerase (1 µl; Clonetech, USA). After an initial denaturation at 95° C for 2 minutes, 
the DNA was amplified by 25 cycles of 95° C for 30 seconds, 55° C for 30 seconds, and 
68° C for 1 minute, with a final elongation at 68° C for 10 minutes on the GeneAmp 
PCR system 9700 (Applied Biosystems, UK). Amplified DNA was sequenced by the 
AHVLA sequencing facility (AHVLA, UK) using primers 3 and 4 (Table 7; Sigma, 
UK) which annealed to the LipL32 gene at base pairs 148 and 62 respectively (5’-3’ 
orientation) and primers 5 and 6 (Table 7; Sigma, UK) which annealed to the LipL32 
gene at base pairs 670 and 740 (5’-3’ orientation) respectively. Resulting sequence files 
were amalgamated into a consensus sequence for LipL32 using Lasergene (DNASTAR, 
USA). The LipL32 gene sequence for strain Kito (determined in this study) was 
compared, using Lasergene (DNASTAR, USA), against the published complete gene 
sequences (from http://www.ncbi.nlm.nih.gov accessed on 12/01/12) of LipL32 from 
strains Hond Utrecht IV (GI: 33589193), RTCC 2805 (GI: 358357257) and Lin (GI: 
48526297). 
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Table 7: List of primers used during this study to detect LipL32 
Primer Sequence* 
1 GGAAACTACCGCAAAGTC 
2 CACCACCGGACTCTAAAA 
3 GTTGATCACAGATCCGTA 
4 TTAGGCTTGGCAGACCAC 
5 GTTGCATCTGTTGGTCTG 
6 TGATCCACTCAAATCCTG 
7 GGGGTACCGTGCTTTCGGTGGTCTGC 
8 CGGAATTCTTACTTAGTCGCGTCAGAAG 
9 CAGATCCGGATATAGTTC 
* All primers listed are in the 5’-3’orientation. All primers obtained from Sigma (UK); restriction 
endonuclease sites for KpnI and EcoRI underlined in primers 7 and 8 respectively. 
 
2.6.4 Cloning 
Cloning of the LipL32 gene into an expression vector, downstream from a Polyhistidine 
tag, was performed using a method modified from Haake et al (2000). Whereby L. 
Kirschneri genomic DNA was substituted with L. interrogans serovar Canicola 
genomic DNA, which also necessitated that the restriction enzymes XhoI and SmaI  be 
substituted with KpnI and EcoRI (and associated primers changed accordingly); in 
addition the expression strain BLR(DE3)/pLysS was substituted for BL21(DE3)/pLysS 
as it was more readily available. PCR was used to amplify the portion of the LipL32 
gene encoding the mature protein beginning with the first residue after the amino 
terminal cysteine. The forward primer, primer 7 (20 pmol; Table 7), contained a 
nucleotide sequence coding for the amino acids following the amino terminal cysteine 
of mature LipL32, including a KpnI restriction endonuclease site (underlined; Table 7). 
The reverse primer, primer 8 (20 pmol; Table 7) contained the nucleotide sequence 
coding for the carboxy-terminal amino acids and the LipL32 stop codon, including an 
EcoRI restriction endonuclease site (underlined). PCR was performed in a 50 µl total 
reaction volume containing 10 x buffer (5 µl; Clonetech, USA), 100 x 
deoxyribonucleotides (0.5 µl; dNTPs; Promega, UK) and Taq polymerase (1 µl; 
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Clonetech, USA); genomic DNA (15 ng) from L. interrogans strain Kito was used as 
template. After an initial denaturation at 95° C for 2 minutes, the DNA was amplified 
by 25 cycles of 95° C for 30 seconds, 53° C for 30 seconds, and 68° C for 1 minute, 
with a final elongation at 68° C for 10 minutes on the GeneAmp PCR system 9700 
(Applied Biosystems, UK). Assessment of PCR product was performed using gel 
electrophoresis (section 2.6.2), product was cleaned using a QIAquick PCR Purification 
Kit (Qiagen, USA) as per the manufacturer’s instructions and DNA concentration 
estimated using a Nanodrop (section 2.6.1). 
 
The amplified lipL32 gene (15.8 µl of cleaned PCR product) and the pRSET C 
(Invitrogen, UK) expression vector (1.5 µg of DNA) were digested with Kpn1 
(Promega, UK), as per manufacturer’s instructions. Reaction mixtures were cleaned 
using a QIAquick PCR Purification Kit (Qiagen, USA) and digested again with EcoRI 
(Promega, UK), as per manufacturer’s instructions. Reaction mixtures were then 
cleaned again using a QIAquick PCR Purification Kit (Qiagen, USA) and quantified 
using a Nanodrop (section 2.6.1). Finally the double digested insert (lipL32 gene) and 
vector (pRSET C) were ligated together using T4 DNA ligase (Promega, UK) as per 
manufacturer’s instructions. The ligation mixture was then transformed into chemically 
competent E. coli BL21 (DE3) pLysS cells, as per manufacturer’s instructions, and 
transformants were selected as described previously (section 2.3.2). 
 
PCR was used to confirm the presence and orientation of the lipL32 insert within the 
pRSET C vector. Plasmid DNA from the recombinant E. coli strain (section 2.6.1) was 
used as template DNA (1 ng) with primers 7 and 9 (20 pmol; Sigma, UK; Table 7) 
which annealed to the 5’ end of LipL32 and pRSET C vector respectively (shown in 
figure 21). PCR was performed in a 20 µl total reaction volume containing Hotstart 
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master mix (10 µl; Promega, UK). After an initial denaturation at 96° C for 15 minutes, 
the DNA was amplified by 25 cycles of 95° C for 30 seconds, 52° C for 30 seconds, and 
72° C for 1 minute, with a final elongation at 72° C for 10 minutes on the GeneAmp 
PCR system 9700 (Applied Biosystems, UK). PCR product was run on a 1% w/v 
agarose gel for confirmation of size (section 2.6.2). 
 
Plasmid diagram of the LipL32-pRSET C construct (Figure 21) was generated using 
SECentral (Sci-Ed, USA). 
 
2.6.5 Expression and purification of LipL32 
For purification of the LipL32 protein; recombinant E. coli was cultured (500 ml) and 
induced with IPTG (section 2.3.2). Cells were centrifuged (6000 x g) for 15 minutes at 
4o C and resuspended in lysis buffer (10 ml; 100 mM sodium phosphate, 6 M guanidine 
hydrochloride, pH 8). Cells were lysed by 6 second pulses of probe sonication 
(amplitude 60) using a Vibra-Cell ultrasonic processor (Sonics and Materials, USA) for 
6 minutes on ice and centrifuged (4000 x g) for 10 minutes at 4o C to remove cellular 
debris. The Polyhistidine tagged LipL32 protein was then purified from the retained 
supernatant using PureProteome Nickel Magnetic Beads (Millipore, UK), a wash buffer 
(50 mM sodium phosphate, 300 mM sodium chloride, 10 mM imidazole, pH 8) and an 
elution buffer (50 mM sodium phosphate, 300 mM sodium chloride, 300 mM 
imidazole, pH 8) according to the manufacturer’s instructions. Eluted protein was 
washed once with phosphate buffered saline (2 ml; 0.1 M PBS, pH 7.2) using a 5 kDa 
MWCO filter (Sartorius Stedim, France) and resuspended to a final volume of 200 µl in 
PBS. 
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2.7 Hamster Model Methodology 
2.7.1 Preparation of protein samples and controls 
Test samples 1-4 (described below) were prepared for assessment of their protective 
immunogenicity in hamsters; five aliquots of each were prepared. Test sample 1 
comprised purified LipL32 protein (380 fmol; quantitation against the N terminal of 
LipL32), from the recombinant E. coli strain (section 2.6.5), resuspended in 0.9% (w/v) 
physiological saline to a final volume of 0.5 ml. Test sample 2 comprised purified 
LipL32 protein (380 fmol of N terminal LipL32), from the recombinant E. coli strain 
(section 2.6.5), resuspended in 0.9% (w/v) physiological saline to a final volume of 0.25 
ml and mixed with Imject Alum adjuvant (0.25 ml; Thermo Scientific, USA). Test 
sample 3 comprised vaccine F diluted 1/40 with 0.9% (w/v) physiological saline to a 
final volume of 0.5 ml as a positive control. Test sample 4 comprised 0.5 ml 0.9% (w/v) 
physiological saline as a negative control. 
 
2.7.2 Immunisation of hamsters with test products 
 Test samples 1-4 (section 2.7.1) were analysed in four separate treatment groups, each 
comprising five hamsters; a fifth untreated group, comprising 5 hamsters was used as a 
control. The hamsters in treatment groups 1-4 were inoculated subcutaneously (as 
previously described in section 2.4.2) with the relevant test sample (0.5 ml; section 
2.7.1); control group 5 did not receive an inoculation. Treatment groups 1-5 were then 
challenged with virulent L. interrogans serovar Canicola (strain Kito) as previously 
described (section 2.4.2). A sixth group, comprising an additional three hamsters which 
were not vaccinated or challenged, were also used as a healthy control for histological 
comparison. All surviving animals in groups 1-6 were euthanised (section 2.4.2) on day 
24, which was 14 days after the fourth hamster in the negative control (group 5) died.  
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2.7.3 Culture of Leptospira from hamster kidneys  
Kidneys were excised from all hamsters at post mortem and dissected for assessment of 
infection. Half were retained for histological processing (section 2.7.4) and half were 
disrupted with a 10 ml syringe and cultured in EMJH media (as in section 2.3.1); 
presence of Leptospira was assessed by eye using a dark field microscope.  
 
2.7.4 Histology 
Samples from liver, spleen and kidney were collected from all hamsters at post mortem 
and fixed in 10% buffered formalin. Subsequent histological processing and analysis 
were performed by a veterinary pathologist (AHVLA, UK). Tissue samples were 
routinely processed and embedded in paraffin wax using a Hypercentre XP tissue 
processor (Thermo Shandon, UK). Consecutive 4 micron thick sections were cut using a 
Leica RM2025 (Leica, Germany) rotary microtome. Sections were stained with 
haematoxylin and eosin, for histopathological examination, and Warthin-Starry silver 
impregnation, for the visualization of leptospires in the tissues (Bancroft and Stevens, 
1996). Renal lesions are indicative of infection and if present were graded according to 
their severity (0 as normal, 1 as minimal, 2 as mild, 3 as moderate and 4 as severe). The 
number of leptospires present on the various tissues were also graded with 0 as absent, 1 
as rare, 2 as few, 3 as numerous and 4 as profuse. Slides were examined in a Leica 
DM4000B microscope (Leica, Germany). Pictures were taken using a Leica DFC480 
digital camera (Leica, Germany) and Leica Application Suite software (Leica, 
Germany); Adobe Photoshop Elements 4.0 (Adobe, USA) was used to adapt images for 
publication. 
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2.7.5 Enzyme-linked immunosorbent assay 
Total blood content of hamsters was extracted at post mortem (section 2.7.2) using 
cardiac puncture; serum was prepared from blood and stored at -20o C. Assessment of 
circulating antibodies in the serum was performed using enzyme-linked immunosorbent 
assays (ELISA). Two antigens were chosen for assessment, purified LipL32 (section 
2.6.5) and whole cell L. interrogans serovar Canicola (strain Kito). LipL32 antigen was 
prepared by diluting purified LipL32 protein (section 2.6.5) in antigen coating buffer 
(0.05 M carbonate-bicarbonate buffer, pH 9.6; Sigma, UK) to a final concentration of 1 
µg/ml (total protein). Whole cell antigen was prepared by culturing (section 2.3.2) L. 
interrogans serovar Canicola (20 ml, strain Kito; ~5 x 108 cells/ml) and collection of 
cells by centrifugation at 4000 x g for 20 minutes at 4o C. Cells were resuspended in 0.1 
M PBS (100 µl; pH 7.2), heat denatured at 95o C for 15 minutes, and diluted in antigen 
coating buffer to a final concentration of 5 µg/ml (total protein). Diluted antigens (100 
µl) were added to the wells of a microtitre plate (Polysorb; Nunc, USA) and incubated 
overnight at room temperature. Plates were washed three times for 1 minute with wash 
buffer (400 µl; 0.1 M PBS pH 7.2, 0.05 % (v/v) Tween-20) and blocked (blocking 
buffer 200 µl; 3 % [w/v] dried skimmed milk in washing buffer) by incubation for 30 
minutes at 37o C. Plates were then washed three more times. Hamster serum was serially 
diluted with buffer (1 % (w/v) dried skimmed milk in washing buffer) from 1/100 to 
1/12800; each dilution (200 µl) was added to the microtitre wells in duplicate (serum 
was added to both antigens). A polyclonal LipL32 antibody from Dr Jarlath Nally 
(UCD, Dublin) was used at a 1/1000 dilution as a positive control for the antigen; 
negative controls including serum with no antigen and empty wells were also used. 
Plates were incubated at 37o C for 1 hour with orbital agitation (50 rpm) prior to 
washing (x3). The protein A/G (ThermoFisher, USA; conjugated to the enzyme 
horseradish peroxidase) was diluted 1/50000 in diluting buffer, and added (200 µl) to 
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the wells of the microtitre plate prior to incubation at 37o C for 30 minutes with orbital 
agitation (50 rpm). Plates were washed (x3) prior to the addition of 
Tetramethylbenzidine (100 µl; TMB) substrate (Sigma, UK); plates were incubated at 
room temperature in the dark for 10 minutes and the reaction stopped by the addition of 
10 % (v/v) H2SO4 (50 µl) to all wells. Plates were read in a MRX Revelation (Dynex 
Technologies, USA) spectrophotometer at a wavelength of 450 nm. A diagram showing 
the ELISA protocol used is shown in Figure 4. 
 
 
Figure 4: ELISA protocol used for the assessment of circulating antibodies in serum 
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Chapter 3  Analysis of Leptospira vaccines 
3.1 Introduction 
Vaccination is widely used to protect against Leptospira infection in animals; however 
the majority of vaccines currently available are serovar specific (Koizumi and 
Watanabe, 2005) and require regular boosters to maintain immunity (Klaasen et al., 
2003). Bi and multivalent vaccines have been developed by blending multiple heat 
killed serovars of Leptospira together during vaccine formulation; however the 
protective effects of such vaccines are limited to the serovars from which they are 
comprised (Koizumi and Watanabe, 2005). In the past the epidemiology of Leptospira 
was such that particular serovars had a higher prevalence in certain species, for example 
serovar Canicola infecting dogs, making it easier to choose which vaccines to 
administer. However it has been observed that these trends can change (Brown et al., 
1996) and with over 230 known pathogenic serovars in circulation (Adler et al., 2011) 
the question arises as to the extent of protection in vaccinated animals.  
 
 ELISA based potency assays (section 1.4) for some Leptospira serovars (Ruby et al., 
1992, Goddard et al., 1986) have been developed; however the majority of Leptospira 
vaccines, particularly those providing protection against serovars Canicola and 
Icterohaemorrhagiae, have to be tested in a hamster model prior to being released onto 
the market. Aside from the ethical and financial implications of testing in this way it is 
not uncommon for batches of vaccine to fail resulting in higher costs for the 
manufacturer and therefore higher prices for the consumer. The biggest problem for the 
industry is that the mechanism of action for these vaccines is poorly defined, hindering 
attempts at new vaccine development and accurate quantification of efficacy.  
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The majority of Leptospira vaccine research in the literature (Wang et al., 2007) 
concentrates on identification of new vaccine targets from the causative organism. The 
proteome and genome of Leptospira interrogans have been determined (Sakolvaree et 
al., 2007, Malmstrom et al., 2009, Nascimento et al., 2004a) and a number of potential 
vaccine candidates have been identified (section 1.2.3). A recent publication has also 
identified lipopolysaccharide (LPS) as a good vaccine candidate and suggests that a 
LPS mutant may be able to provide cross protection against heterologous Leptospira 
serovar challenge (Srikram et al., 2011). 
 
This approach to vaccine development can be affective; however it is also time 
consuming, costly and to date has failed to produce a longer lasting, cross serovar 
protective Leptospira vaccine. A more effective approach would be to investigate how 
existing Leptospira vaccines function. A number of previous proteomic studies have 
investigated how vaccines provide immunological protection (Ceccarini et al., 2000, 
Vaughan et al., 2006); however, comparative analysis of the protein content of multiple 
Leptospira vaccines has not been previously reported. 
 
This chapter focuses on analysing the LPS and protein components of five L. 
interrogans serovar Canicola vaccines, the primary objective being to identify common 
elements that may be used for the development of an in vitro potency test. In addition, a 
definitive proteomic analysis of vaccine protein content may offer insights into how 
existing vaccines work and how they could be made more efficacious. 
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3.2 Results 
3.2.1 Evaluation of vaccine LPS and protein content  
Five vaccines (A-E) which had passed the in vivo vaccine batch potency test and been 
released for commercial sale, were purchased from different manufacturers for analysis 
(Table 8; in vivo potency data not available). The protein content of vaccines A-E was 
determined using the Bradford assay (Figure 5); the limit of detection for the Bradford 
assay was calculated (section 2.1) as 0.01 mg/ml, whereas the limit of quantification 
was calculated (section 2.1) as 0.05 mg/ml. The protein content of vaccine B was very 
low (0.07 ± 0.01 mg/ml; mean ± 1 SD) making 2D-LC/MS analysis difficult as only 6 
µg of protein could be tryptically digested and analysed for each replicate, compared to 
the 100 µg of protein used for the other vaccines. Gel electrophoresis (Figure 6) of 
vaccines A-E, with Coomassie staining for protein, was consistent with the data from 
the Bradford assay confirming that vaccine B had a lower protein content than the other 
vaccines analysed; the maximum well volume (36 µl) was loaded for vaccine B which 
equates to 2.5 µg. Gel spots were cut out and analysed on the Q-ToF (section 2.5.3); 
proteins detected in the visible bands (Figure 6) were all identified as albumin 
(Appendix 1), which is likely to be left over from the growth media used to culture 
Leptospira (section 1.3.5). A complete table detailing all the proteins identified in the 
vaccine gel spots is listed in Appendix 1. 
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Table 8: Composition and route of administration for five vaccines (A-E) derived from the National Office of Animal Health (NOAH) Compendium (Accessed on 
17/11/11).   
Vaccine* Formulation Adjuvant Preservative Immunises against Serovars Route(s) of administration 
A Inactivated Bacteria Not Known Thiomersal Canicola & Icterohaemorrhagiae Subcutaneous 
B Inactivated Bacteria Aluminium Hydroxide Not Known 
Canicola & 
Icterohaemorrhagiae 
Subcutaneous or 
Intramuscular 
C Outer Membrane Coat Protein Not Known Not Known 
Canicola & 
Icterohaemorrhagiae Subcutaneous 
D Inactivated Bacteria Not Known Not Known Canicola & Icterohaemorrhagiae Subcutaneous 
E Inactivated Bacteria Not Known Thiomersal Canicola & Icterohaemorrhagiae Subcutaneous 
*Vaccine and manufacturer names excluded for confidentiality reasons. Note all vaccines listed are for use in dogs. 
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Figure 5: Concentration of protein and LPS in vaccines A-E (as sold) as determined by the 
Bradford and LAL assays respectively.  
Note: Two replicates of each vaccine were analysed for each assay; mean and standard error of the 
mean are shown. 
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Figure 6: Vaccines A-E (lanes 2-6; 20 µg. Lane 3 contains 2.5 µg) run on a 4-12% NUPAGE gel 
stained with Coomassie blue to detect protein (left) and Silver to detect LPS (right).  
Note: Lanes 1 and 9 contain a 3.5 kDa protein ladder and lanes 7-8 contain 10 µg and 500 ng E. coli 
LPS respectively as positive controls. 
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The LPS content of vaccines A-E was evaluated by PAGE using a LPS specific silver 
stain (Figures 5-6) which showed that vaccine C did not contain any detectable LPS. E. 
coli LPS was purchased (Sigma, UK) for use as a control as Leptospira derived LPS 
could not be obtained; the upper and lower limits of E. coli LPS detection were 
determined to be 10 µg and 500 ng respectively by systematically testing a range of 
concentrations.  
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Figure 7: Evaluation of specificity of silver staining for LPS.  
Note: Undigested (left) and proteinase K digested (right) aliquots of vaccines A-E (lanes 2-6; 36 µl; 
lanes 5 and 3 in right hand gels contain vaccines B and D respectively) run on a 4-12% NUPAGE 
gel stained with Coomassie blue to detect protein (top) and Silver to detect LPS (bottom). Lanes 1 
and 9 contain a 3.5 kDa protein ladder and lanes 7-8 contain 500 ng and 10 µg E. coli LPS 
respectively as positive controls. 
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To determine the specificity of the silver stain used for LPS, proteinase K digested 
aliquots (36 µl) of vaccines A-E were subjected to gel electrophoresis and stained for 
both protein (Coomassie stain) and LPS (silver stain) and compared to non-proteinase K 
digested aliquots (Figure 7). Proteins were observed in the non-digested aliquots of the 
vaccines, when stained with coomassie (Figure 7), but not in the digested aliquots 
suggesting that complete protein digestion had occurred. The pattern of banding seen in 
the silver stained gels however was substantially the same between the digested and 
non-digested vaccines indicating that the silver stain used is specific to LPS.  
 
For corroboration, the LAL assay (Charles River, UK) was also performed on vaccines 
A-E; a calibration curve (Figure 8) using E. coli derived LPS (Charles River, UK) was 
constructed using Prism 4 (Graphpad, USA) over the tested concentration range (0.33-
3333 ng/ml) allowing determination of sample concentration (Figure 5) by 
interpolation. The limit of detection for the LAL assay was calculated (section 2.1) as 
0.08 ng/ml, whereas the limit of quantification was calculated (section 2.1) as 0.33 
ng/ml. LPS was not detectable in vaccine C which is in agreement with the results from 
the silver stained gels (Figures 5-6). 
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Figure 8: Nonlinear regression of LPS calibration standards using the limulus amebocyte lysate 
assay detected at 405 nm.  
Note: Two replicates of each standard were analysed for each concentration; mean and standard 
error of the mean are shown. 
 
3.2.2 Vaccine Preparation 
Removal of interfering agents from vaccines A-E (Table 8), such as adjuvant and 
preservative, was required prior to proteomic analysis. Molecular weight cut off filters 
(MWCO; 5 KDa) were therefore used to reduce the concentration of low molecular 
weight contaminants such as Aluminium hydroxide (78 Da) and Thiomersal (405 Da). 
Strong cation exchange chromatography was subsequently used to assess the effect of 
MWCO washing on peak resolution and intensity (Figure 9); vaccine D was arbitrarily 
chosen for assessment as a larger volume of this vaccine was available for analysis. 
Separation of vaccine D was shown to be improved by prior washing of the vaccine 
once in a molecular weight cut off concentrator (Figure 9) with an additional peak 
observed at 13.81 minutes. However additional washes led to an overall decrease in 
peak intensity and separation. Acetone precipitation of protein from vaccine D was also 
assessed however no improvement of peak resolution was observed (Figure 9). 
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Figure 9: Strong cation exchange separation of trypsin digested vaccine D when prepared using different conditions.  
Note: Chromatograms recorded at 280nm. 
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3.2.3 Strong Cation Exchange Chromatography 
Separation of tryptic peptides from vaccines A-E showed a high degree of 
reproducibility between the chromatograms of the three technical replicates, an example 
of which can be seen in Figure 10 for vaccine D. Direct comparison of the different 
vaccines however, revealed considerable disparity (Figure 11); this can most likely be 
attributed to variation in the manufacturing process used to create the different vaccines 
however a distinct peak with a retention time of ~14 minutes was observed in vaccines 
A, C, D and E.  Note each vaccine has a different scale in figure 11 due to the high 
intensity of peaks in vaccine C. 
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Figure 10: Strong cation exchange separation of three technical replicates of vaccine D.  
Note: Chromatograms recorded at 280nm. 
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Figure 11: Strong cation exchange separation of vaccines A-E.  
Note: Chromatograms recorded at 280nm 
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3.2.4 Reverse phase HPLC-MSn  
SCX fractions were analysed by reversed phase HPLC-MSn with reproducibility being 
assessed by the analysis of a known synthetic peptide standard in each assay (Table 9, 
figure 12). Blanks before and after each run of samples (a run being defined as 15 SCX 
fractions) were used to prevent sample carryover and to confirm that no buffer or other 
equipment issues were occurring. 
 
Table 9: Synthetic peptide controls used to assess the performance of RP-HPLC separation and Q-
ToF detection.  
Molecular Precursor Retention 
Mass ion Time Number* Peptide Sequence 
(Da) (m/z) (min) 
1 MRFA 523.26 262.64 12.36 
2 AVDQLNEQSSEPNIYR 1861.88 931.95 19.29 
3 VTALYEGFTVQNEANK 1782.88 892.45 24.48 
4 ARPQELPFLASIQNQGR 1924.03 642.35 29.75 
5 ISVNNVLPVDFNLMQQK 1958.03 980.02 36.95 
6 NYINQYSEVAIQMVMHMQPK 2423.14 808.72 38.47 
*Peptide numbers correspond to ion chromatograms shown in figure 12. 
 
An example of ion chromatograms for SCX fractions 1-15 (Vaccine D, replicate 1), 
collected at one minute intervals between 8 and 22 minutes, is shown in Figure 13. The 
intensity of the fractions is consistent with the corresponding peaks observed in the 
SCX chromatograms of vaccine D (Figures 9-10). 
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Figure 12: Total (TIC) and extracted (EIC) ion chromatograms (smoothed) of a synthetic quality 
control peptide mix (100 mg/ml; comprising synthetic peptides 1-6, Table 9).  
Note: Peptides were separated by reversed phase chromatography and detected on a Q-TOF mass 
spectrometer; amino acid sequences, masses, precursor ions and retention times for peptides 1-6 
are given in Table 9. 
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Figure 13: Total ion current chromatograms (TIC) of tryptic peptides from SCX fractions 1-15 
(vaccine D, replicate no. 1) detected on a Q-ToF mass spectrometer. 
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3.2.5 Database comparison 
Leptospira interrogans serovars Copenhageni and Lai are the only L. interrogans 
serovars to have been genome sequenced to date (Nascimento et al., 2004b, Ren et al., 
2003); comparative analysis has revealed 99% sequence identity between protein coding 
genes (Nascimento et al., 2004a).  
 
Since serovar Canicola has not been sequenced, three protein databases were selected 
for comparison in this study (Table 10) to determine which yielded optimal 
identifications when interrogated with mass spectra from vaccine D using Spectrum 
Mill (Agilent). The NCBI non-redundant database and the Uniprot database were 
chosen as they were both known to contain multiple proteomes from different species. A 
custom database derived from chromosomes I and II of Leptospira interrogans serovar 
Copenhageni, was arbitrarily chosen due to its phenotypic similarity to serovar Canicola 
[both serovars are reported to infect dogs (Defra, 2010)] 
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Table 10: Comparison of proteins identified in vaccine D when searched against different databases.  
Database Accession 
Number Protein identification Species NCBInr UniProt Serovar Copenhageni 
P92916 
Bifunctional 6(G)-
fructosyltransferase/2,1-
fructan:2,1-fructan 1-
fructosyltransferase  
A. cepa - + - 
121704634 RSC Complex Subunit (RSC1), Putative A. clavatus + - - 
P42246 
Uncharacterized ABC 
transporter ATP-
binding protein ycbN  
B. subtilis - + - 
27806789 Transthyretin Precursor B. taurus + - - 
30794280 Serum Albumin Precursor B. taurus + - - 
94966811 Alpha-1-Acid Glycoprotein Precursor B. taurus + - - 
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160332365 
RecName: Full=Serpin 
A3-1: AltName: 
Full=Endopin-1A: 
AltName: Full=Muscle 
endopin-1A: 
Short=mEndopin-1A: 
Flags: Precursor 
B. taurus + - - 
O46375 Transthyretin  B. taurus - + - 
P02769 Serum albumin  B. taurus - + - 
P41361 
Antithrombin-III 
OS=Bos taurus 
GN=SERPINC1 PE=1 
SV=2 
B. taurus - + - 
Q3SZR3 Alpha-1-acid glycoprotein  B. taurus - + - 
66806199 MAP Kinase Phosphatase D. discoideum + - - 
20129847 CG1371 D. melanogaster + - - 
28590 Unnamed Protein Product H. sapiens + - - 
116328028 Endoflagellar Filament Core Protein 
L. borgpetersenii serovar Hardjo-
bovis + - - 
45645172 Major Outer Membrane Protein L. interrogans  + - - 
48995769 Major Outer Membrane Protein L. interrogans serovar Canicola + - - 
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45656096 
Peptidoglycan 
Associated Cytoplasmic 
Membrane Protein 
L. interrogans serovar Copenhageni - - + 
45656175 Cell Wall Hydrolase L. interrogans serovar Copenhageni - - + 
45656272 Putative Lipoprotein L. interrogans serovar Copenhageni +  + 
45656311 Hypothetical Protein LIC10411 L. interrogans serovar Copenhageni - - + 
45656396 Putative Lipoprotein L. interrogans serovar Copenhageni - - + 
45656890 LipL71 L. interrogans serovar Copenhageni - - + 
45657043 Dihydrolipoamide Dehydrogenase L. interrogans serovar Copenhageni - - + 
45657230 LipL32 L. interrogans serovar Copenhageni - - + 
45657753 Flagellin Protein L. interrogans serovar Copenhageni - - + 
45658793 LipL41 L. interrogans serovar Copenhageni - - + 
45658988 Hypothetical Protein LIC13166 L. interrogans serovar Copenhageni - - + 
24212922 OmpA Family Lipoprotein L. interrogans serovar Lai + - - 
24213171 Hypothetical Protein LA_0471 L. interrogans serovar Lai + - - 
Q0W6M2 Probable deoxyribose-phosphate aldolase  Methanogenic Archaeon - + - 
57619174 Ceruloplasmin Precursor O. aries + - - 
Q9XT27 Ceruloplasmin  O. aries - + - 
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57335404 Type III Vimentin P. aethiopicus + - - 
34540298 Hypothetical Protein PG0482 P. gingivalis W83 + - - 
39933667 Putative Carboxyl-Terminal Protease R. palustris + - - 
21218825 Transcriptional Repressor Protein S. coelicolor A3(2) + - - 
136429 
RecName: 
Full=Trypsin: Flags: 
Precursor 
S. scrofa + - - 
P00761 Trypsin  S. scrofa - + - 
A8F866 Alanyl-tRNA 
synthetase  T. lettingae - + - 
Total Conserved Proteins 21 10 11 
Note + indicates protein detection. 
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The NCBI database identified 21 proteins in vaccine D whereas the Uniprot and custom 
databases identified 10 and 11 proteins respectively (Table 10). However, only 6 of the 
21 proteins identified using the NCBI database were of Leptospira origin and none of 
the proteins identified using the Uniprot database were specific to Leptospira; the 
custom database was therefore utilised for subsequent searches as it resulted in a higher 
number of Leptospira specific identifications. 
 
3.2.6 Search Engine Comparison 
Identification of vaccine proteins required that mass data be interrogated using a 
suitable search engine. For the purposes of this study Spectrum Mill (Agilent), OMSSA 
(NCBI) and Mascot (Matrix Science) were chosen for comparison (Table 11) to 
determine which gave the most reliable identifications. Mass spectra for vaccine D was 
interrogated against the custom serovar Copenhageni database using equivalent 
conditions for each search engine (section 2.5.4) and results were exported as excel files 
for bioinformatic analysis.  
 
Table 11:  Comparison of the number of proteins identified in vaccine D and its percentage of false 
discoveries using different search engines 
Search Engine Mean Proteins ± 1 SD % False Discovery Rate ± 1 SD 
Spectrum Mill 21 ± 5 2.9 ± 1 
OMSSA 44 ± 14 23.8 ± 7 
Mascot 48 ± 8 12.8 ± 3 
 
The number of proteins identified using OMMSA and Mascot were higher in vaccine D 
than in Spectrum Mill; however, the false discovery rates calculated for the two search 
engines were also substantially higher. Since the same search parameters were selected 
across the three programs it is apparent that Spectrum Mill is more stringent, under 
these conditions, which results in more reliable data. 
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3.2.7 Exclusion List Comparison 
Previous gel electrophoresis (section 3.2.1) revealed albumin to be present at a high 
abundance in vaccines A-E (Figure 6, Appendix 1). In an effort to increase the 
identification of Leptospira proteins an exclusion list (section 2.5.2) method, to exclude 
known albumin precursor ions from being subjected to MS/MS, was trialled using 
vaccine D (which had been washed 3 times with a molecular weight cut off 
concentrator). The resulting mass spectra was searched against the NCBInr database in 
addition to the serovar Copenhageni databases to allow identification of albumin (Table 
12). The mean percentage coverage of albumin increased by 9% when the exclusion list 
was used however no significant difference was observed in the number of proteins 
detected compared to when not using an exclusion list (Table 12).  
 
Table 12: Comparison of the number of proteins identified in vaccine D when using an albumin 
exclusion list when searched against different databases.  
Database Albumin Exclusion  Mean Total Proteins ± 1 SD P Value 
+ 53 ± 25 NCBInr 
- 50 ± 16 0.91 
+ 6 ± 2 Serovar 
Copenhageni 
- 5 ± 3 0.77 
Note + indicates that the exclusion list was utilised. 
 
Further experimentation using albumin exclusion lists was precluded due to the low 
scan speed of the mass spectrometer used; subsequent analysis of vaccines was 
therefore performed without the use of an exclusion list. 
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3.2.8 Vaccine Proteome Analysis 
The protein content of vaccines A-E were analysed using 2D-LC/MS; proteins present 
across all three technical repeats were then compiled using Microsoft Access to give the 
proteome of each vaccine (Appendix 2). 
 
Proteins present in all five of these vaccine proteomes were determined using Microsoft 
Access (Table 13) and their respective abundances calculated using the normalised 
spectral abundance factor. Although the total number of proteins in each varied 
considerably (Table 13) two proteins, LipL32 and flagellin, were found to be common 
to all five vaccines. Due to the low number of proteins identified in vaccine B and their 
correspondingly low coverage a separate comparison of vaccines A and C-E was also 
performed, which identified two additional conserved proteins (shaded area, Table 13) 
LipL41 and hypothetical protein LIC10411. 
 
Table 13: Conserved proteins present in commercially available vaccines from five different 
manufacturers (A-E).  
Accession  Protein Relative Abundance  (Mean ln(NSAF) 
Number  Identification A B C D E 
-4.11 -2.64  -2.48  -2.22  -2.88  45657230 LipL32  (27) (6) (27) (24) (19) 
-3.41  -2.44  -3.01  -2.35  -2.59  45657753 Flagellin Protein (31) (5) (17) (26) (21) 
-3.35  -2.09  -2.08 -2.39  45658793 LipL41  (33) ND (31) (31) (27) 
LIC10411  -2.45  -3.13  -2.96  -3.03  
45656311 (Hypothetical) (39) ND (15) (15) (15) 
Total Proteins (mean ± 1 SD) 221±31 9±8 34±4 21±5 34±17 
Higher ln(NSAF) values indicate greater abundance. ND = Protein not detected. Figures in 
brackets represent mean percentage protein coverage. Note: Shaded areas represent additional 
conserved proteins identified when vaccine B is excluded from comparison. 
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3.3 Discussion 
An ELISA based approach was previously developed to determine the potency of 
Leptospira vaccines in vitro (Ruby, 1999). Though the ELISA format was ultimately 
unsuccessful due to issues with adjuvant interference (section 1.4.1) the monoclonal 
antibodies developed for the assay were established to be reacting to a specific LPS-like 
moiety; further it was also established that these monoclonal antibodies were serovar 
specific. Since it is theorised that the microscopic agglutination test (MAT) used for 
identification of Leptospira serovars reacts specifically against LPS (Guerreiro et al., 
2001) and that Leptospira vaccines are known to be serovar specific (Koizumi and 
Watanabe, 2005) it appeared reasonable that the active component of the vaccines, 
responsible for conferring protective immunity might be LPS based.  
 
LPS was therefore investigated as a possible biomarker for potency in vaccines A-E. 
Extraction of the LPS component of the vaccines and analysis using a MALDI-ToF (Yi 
and Hackett, 2000) mass spectrometer was planned; however initial evaluation of 
vaccine LPS content using PAGE with silver staining suggested that it was not common 
to all vaccines, which was confirmed through subsequent analysis using the LAL assay. 
This absence of detectable LPS in vaccine C suggests that, at least in this vaccine, it 
may not be necessary to induce protective immunity against Leptospira; further work is 
required to elucidate its function in the other vaccines analysed which is outside the 
remit of this project.  
 
The amount of validation required for an in vitro potency test to be approved by the 
European pharmacopeia, which would be a prerequisite prior to implementation by 
vaccine manufacturers, would be both time consuming and costly. Therefore it would 
not be practical to develop an LPS based in vitro potency test if it could not be 
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universally applied to all Leptospira vaccines and as a result further work into the 
analysis of the vaccines LPS content was not performed.  
 
Since protein derived from L. interrogans is known to be highly immunogenic and 
capable of providing cross protection against different serovars (Sonrier et al., 2000) a 
method to characterise the protein content of the Leptospira vaccines was sought. A 2D-
LC/MS approach was chosen, as good results had been previously reported (Coldham 
and Woodward, 2004, Vaughan et al., 2006, Chao et al., 2007) in the proteomic analysis 
of bacteria using a similar method, and a technique for cleaning the samples prior to 
analysis developed. Subsequent interrogation of mass spectra for protein identity was 
optimised through evaluation of multiple protein databases and search programmes 
resulting in a de novo approach for the analysis of Leptospira vaccine proteomes using 
2D-LC/MS.  
 
The total protein content of vaccine B was found to be much lower than that found in 
the other vaccines when assessed using the Bradford assay. It was therefore necessary to 
analyse a smaller protein content of vaccine B using 2D-LC/MS which could account 
for the lower number of proteins identified (Table 13). Subsequent proteomic analysis 
of vaccines A and C to E has revealed four conserved proteins. Of these it is LipL32, 
LipL41 and the flagellin protein that are of interest as they are known to be potential 
immunogens (Haake et al., 1999, Hauk et al., 2008). When vaccine B was included in 
the comparison the only proteins identified as being conserved were flagellin and 
LipL32. 
 
Flagellin is a constituent part of the flagellum and is therefore a highly abundant protein 
in bacteria. Bacterial flagellin typically stimulates the innate immune response (Hayashi 
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et al., 2001) however it can also play a role in the adaptive immune system (Letran et 
al., 2011). The immunogenic potential of flagellin is such that it makes an excellent 
adjuvant candidate (McSorley et al., 2002, Cuadros et al., 2004) when constructing 
vaccines; though its use in the creation of Leptospira vaccines has not been widely 
reported.  
 
LipL32, also known as hemolysis associated protein-1 (Hap-1), is a major surface 
expressed outer membrane protein (Cullen et al., 2005) found in pathogenic Leptospira 
species (Haake et al., 2000). It is known to provide cross protection against Leptospira 
interrogans (Branger et al., 2001) in the gerbil model and various different methods for 
presenting it as a vaccine have been trialled (Branger et al., 2005, Seixas et al., 2007b). 
A recent study (Lucas et al., 2011) has reported that recombinant LipL32 does not 
confer protective immunity against leptospirosis in hamsters; however this study was 
limited to three serovars and did not include the Canicola serovar. 
 
In conclusion 2D-LC/MS has been confirmed to be an effective tool for vaccine 
analysis and a technique for the analysis of vaccines proteomes has been demonstrated. 
Vaccines from five major manufacturers have been assessed and two conserved 
proteins, LipL32 and flagellin, have been identified. Both of these conserved proteins 
are known to be highly immunogenic and may present good targets for the development 
of an in vitro potency test. Further work is required to ascertain if there are any 
differences in these proteins between batches of vaccine which pass the hamster 
challenge test and batches that fail. 
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Chapter 4  Identification of LipL32 as a biomarker for L. 
interrogans serovar Canicola vaccine potency 
4.1 Introduction  
Proteomics has been used as a tool for biomarker discovery for some time in a diverse 
range of fields including (but not limited to) bacterial identification (Welker, 2011), 
cancer (Zeng et al., 2011), autoimmune (De Franceschi et al., 2011), cardiac (Zhang et 
al., 2011), respiratory (O'Neil et al., 2011) and neurologic diseases (Dudley et al., 2011). 
Identified biomarkers can be used both for therapeutic purposes, such as the discovery 
of novel drug targets, and prognostically allowing better identification and stratification 
of disease states (which in turn can lead to more personalised disease treatment with 
obvious health benefits). To date however its only application in Leptospira 
vaccinology has been in the development of novel therapeutic agents.  
 
Our previous studies (Chapter 3) established that 2D-LC/MS could be used to analyse 
the protein content of serovar Canicola vaccines. This chapter focuses on applying label 
free, quantitative proteomic techniques to characterise the range and abundance of 
proteins present in batches of a L. interrogans serovar Canicola vaccine. The primary 
aim of this chapter is to prove that protein biomarkers for vaccine potency are present in 
both passed and failed vaccine batches and can be quantitatively identified using mass 
spectrometry. 
 
 97 
4.2 Results 
4.2.1 Bacterial culturing conditions 
Growth was assessed by dark field microscopy (section 2.3.3) in triplicate for the Hond 
Utrecht IV strain of Leptospira interrogans serovar Canicola (AHVLA, UK) over a 9 
day period, to determine the optimum point at which cell numbers peaked. A nonlinear 
regression growth curve was then created using the program Graphpad Prism 4 (Figure 
14). 
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Figure 14: Nonlinear regression growth curve for Leptospira interrogans serovar Canicola.  
Note: Results are presented as the mean and the standard error of the mean. 
 
The end of log phase, day 7, was chosen as the optimal time point for maximal protein 
extraction due to the high concentration of cells present. Two fractions, approximately 
corresponding to the cytosol (soluble fraction) and cell membrane (precipitated 
insoluble fraction) were extracted from the bacteria (section 2.3.5), and assessed for 
protein content using the Bradford assay (Table 14). 
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Table 14: Concentration of protein in cellular extracts of Leptospira interrogans serovar Canicola. 
Extract N Concentration (mg/ml; mean ± 1SD) 
Soluble 3 4.77 ± 1.18 
Precipitated 3 60.53 ± 6.26 
 
4.2.2 Leptospira Proteome Characterisation 
The protein content of the soluble and precipitated extracts of serovar Canicola were 
analysed using 2D-LC/MS (see section 2.5.2) and identified by searching against the 
serovar Copenhageni protein database. Proteins present across all three technical repeats 
were then compiled using Microsoft Access to give the proteome of each extract; 952 ± 
59 and 666 ± 8 proteins (mean ± 1 SD) were detected between the cytosol and 
precipitated extracts respectively, the combined fractions yielded 1015 unique proteins 
(Appendix 3). The 25 top most abundant proteins (according to their NSAF score) in 
each extract are shown in tables 15 and 16; the flagellin and LipL32 proteins previously 
identified in vaccines A-E (Chapter 3) were present in both extracts. Detection of 
identical proteins in both the soluble and precipitated extracts can be attributed to 
overlap in the extraction process, due to incomplete fractionation of the two extracts. 
The total serovar Canicola proteome (i.e. the consensus of proteins identified in the two 
extracts) was characterised through grouping the proteins by their functional annotation 
(Figure 15) as determined using PIR (section 2.5.6). The serovar Canicola proteome 
determined in this study was subsequently compared to other Leptospira proteomes 
available in the literature (Table 17). A venn analysis of serovar Canicola with serovars 
Pomona (Vieira et al., 2009) and Copenhageni (Eshghi et al., 2009) was also performed 
(Figure 16), LipL32 was present in all three serovars analysed; protein lists for the other 
studies listed in table 17 were unavailable online precluding them from analysis.  
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Table 15: Top 25 most abundant serovar Copenhageni proteins in the cytosol extract of serovar Canicola.  
Accession  Protein  Primary Protein Protein Length  Mean No.  Mean  Mean  
Number identification Function (Amino Acids) of peptides % Coverage ln(NSAF)* 
45657213 Chaperonin Groel Nucleotide binding  546 307 63.33 -3.95 
45658705 Elongation Factor Tu Hydrolase activity 401 206.33 55.67 -4.04 
45656891 Anti-Sigma Factor Antagonist Protein binding  112 42.67 51 -4.34 
45657831 Thioredoxin Electron carrier activity 104 38.33 46.67 -4.37 
45657930 Cysteine Synthase Catalytic activity 309 83.33 56.33 -4.68 
45657429 Rna-Binding Protein Nucleic acid binding  76 17 28.33 -4.88 
45656311 Hypothetical Protein LIC10411 Binding  157 31.67 47.67 -4.99 
45657838 Rna-Binding Protein Nucleotide binding 92 17.33 72.33 -5.05 
161621774 Malate Dehydrogenase Catalytic activity 326 62 56.33 -5.05 
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45656263 
Electron Transfer 
Flavoprotein 
Alpha-Subunit 
Cofactor binding 319 56.67 41 -5.11 
45659145 
Nucleoside 
Diphosphate 
Kinase 
Nucleotide binding  137 22.67 44.33 -5.17 
45656303 
Riboflavin 
Synthase Beta 
Chain 
Transferase activity  151 25.33 48.33 -5.22 
45658676 
Dna-Directed Rna 
Polymerase 
Subunit Alpha 
Transferase activity  325 51 52 -5.23 
45657230 LipL32 Unknown 272 39.67 44.33 -5.3 
45657300 
Peptidyl-Prolyl 
Cis-Trans 
Isomerase 
Isomerase activity  129 18.67 52 -5.31 
45657237 Hypothetical Protein LIC11359 Oxidoreductase activity  392 53.33 41.67 -5.37 
45657363 Chemotaxis Protein Unknown 154 20.33 22.33 -5.4 
 101 
45659065 Isocitrate Dehydrogenase Ion binding 398 53 44.33 -5.4 
45657214 Co-Chaperonin Groes Nucleotide binding  96 12.67 45.33 -5.41 
45658176 
Putative 
Lactoylglutathione 
Lyase 
Lyase activity  152 19.33 40.33 -5.44 
45657753 Flagellin Protein Structural molecule activity  282 34 42 -5.49 
45658793 LipL41 Binding  355 43 32 -5.49 
45655803 Hypothetical Protein LIC20223 Unknown 143 17 11 -5.5 
45656176 Elongation Factor G Hydrolase activity 706 84.33 41.33 -5.5 
45658048 UDP-Glucose 4-Epimerase Catalytic activity 330 40 35 -5.5 
*Higher ln(NSAF) values indicate greater abundance. 
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Table 16: Top 25 most abundant serovar Copenhageni proteins in the precipitated extract of serovar Canicola.  
Accession  Protein  Primary Protein Protein Length  Mean No.  Mean  Mean  
Number identification Function (Amino Acids) of peptides % Coverage ln(NSAF)* 
45656311 
Hypothetical 
Protein 
LIC10411 
Binding  157 53.67 67.33 -3.63 
45657230 LipL32 Unknown 272 58.67 52.67 -4.09 
45657489 
Arsr Family 
Transcriptional 
Regulator 
Nucleic acid binding  99 20.33 59 -4.18 
45658793 LipL41 Binding  355 68.67 59.33 -4.2 
45657213 Chaperonin Groel Nucleotide binding  546 82.33 52 -4.45 
45656006 
Hypothetical 
Protein 
LIC10095 
Unknown 118 15.33 18 -4.61 
45657363 Chemotaxis Protein Unknown 154 19.67 22 -4.61 
45659005 
Methyl-
Accepting 
Chemotaxis-
Like 
Unknown 127 17 54.67 -4.61 
45656891 
Anti-Sigma 
Factor 
Antagonist 
Protein binding  111 13.33 37 -4.7 
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45656096 
Peptidoglycan 
Associated 
Cytoplasmic 
Membrane 
Protein 
Unknown 195 22 66.33 -4.74 
45657753 Flagellin Protein Structural molecule activity  282 31.33 48.67 -4.75 
45656767 
Hypothetical 
Protein 
LIC10876 
Unknown 183 19 34.67 -4.82 
45657214 
Co-
Chaperonin 
Groes 
Nucleotide binding  96 8.67 50.33 -4.96 
45658705 Elongation Factor Tu Hydrolase activity 401 36.33 48.67 -4.96 
45657123 
F0F1 Atp 
Synthase 
Subunit Delta 
Transporter activity  186 15 28.33 -5.07 
45657432 
50S 
Ribosomal 
Protein L19 
Structural molecule activity  138 11.33 30.67 -5.07 
45658702 
50S 
Ribosomal 
Protein L4 
Structural molecule activity  211 17 33.67 -5.07 
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45657374 
Hypothetical 
Protein 
LIC11499 
Unknown 80 6.33 53 -5.09 
45656646 
50S 
Ribosomal 
Protein 
L7/L12 
Structural molecule activity  127 9.67 35 -5.14 
45657429 Rna-Binding Protein Nucleic acid binding  76 5.67 21 -5.16 
161621777 
F0F1 Atp 
Synthase 
Subunit Alpha 
Nucleotide binding  503 36 41.67 -5.19 
45656645 
50S 
Ribosomal 
Protein L10 
Unknown 177 12 29 -5.25 
45658988 
Hypothetical 
Protein 
LIC13166 
Unknown 306 20.67 34.67 -5.25 
45655941 
Hypothetical 
Protein 
LIC10027 
Unknown 234 18 18 -5.26 
45656741 
30S 
Ribosomal 
Protein S2 
Structural molecule activity  294 19.67 47.67 -5.27 
*Higher ln(NSAF) values indicate greater abundance. 
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Other Genome Annotation Nucleotide Binding Catalytic Activity 
Transferase Activity Hydrolase Activity Oxidoreductase Activity 
Ion Binding Nucleic Acid Binding Transporter Activity 
Peptidase Activity Signal Transducer Activity Metal Cluster Binding 
Electron Carrier Activity Protein Binding 
 
Figure 15: Number of proteins identified in the total L. interrogans serovar Canicola proteome within different functional groups as determined by gene annotation using 
PIR. 
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Table 17: Comparison of the total number of Leptospira proteins identified in this project with previous studies. 
Reference Species Strain Leptospira Proteins Identified 
(Eshghi et al., 2009) L. interrogans serovar Copenhageni Fiocruz L1-130 563 
(Vieira et al., 2009) L. interrogans serovar Pomona LPF 108 
(Malmstrom et al., 2009) L. interrogans serovar Copenhageni Fiocruz L1-130 2221 
(Cao et al., 2010) L. interrogans serovar Lai 56601 2540 
(Zhong et al., 2011a) L. interrogans serovar Lai IPAV 2608 
(Zhong et al., 2011a) L. interrogans serovar Lai 56601 2673 
This Study L. interrogans serovar Canicola Hond Utrecht IV 1015 
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Figure 16: Venn comparison of total number of proteins identified in this study against previous 
studies by Eshghi et al (2009) and Vieira et al (2009). 
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4.2.3 Identification of LipL32 as a biomarker for potency in serovar Canicola 
vaccines 
Five batches of vaccine C were assessed (section 2.4.2) for their protective effects 
against L. interrogans serovars Canicola and Icterohaemorrhagiae (Table 18), further 
batches were unavailable for testing. 
 
Table 18: Hamster potency test performed for five batches of Vaccine C against two serovars of 
Leptospira interrogans.  
Vaccine C   Serovar Canicola   Serovar Icterohaemorrhagiae  
 Batch 
Name  
 Hamsters 
Died  
 Test 
Outcome  
 Hamsters 
Died  
 Test 
Outcome  
 PH1  0 Pass 1  Pass  
 PH2  0 Pass 1  Pass  
 PH3  2 Fail 1  Pass  
 PH4  2 Fail 1  Pass  
 PH5  0 Pass 2  Fail  
Note at least four hamsters had to survive the test for it to pass. 
 
Serovar Copenhageni proteins present in batches of vaccine C which had passed (PH1) 
and failed (PH3) the in vivo potency test (when challenged against serovar Canicola) 
were identified using 2D-LC/MS. Proteins present across all three technical repeats 
were then compiled using Microsoft Access to give the Leptospira proteome of each 
vaccine batch (Tables 19 and 20). Proteins present in both of these batches were then 
determined (Table 21) and their respective abundances calculated via spectral counting 
using the normalised spectral abundance factor (NSAF). The LipL32 and flagellin 
proteins identified in vaccines A-E (Chapter 3) and the serovar Canicola proteome 
(section 4.2.2) were present in both batches of vaccine C. Based on the NSAF LipL32 
and Histidine Kinase Sensor Protein were both shown to be present at a higher 
abundance (p ≤0.05) in the batch of vaccine C which had passed the in vivo potency test 
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(PH1) compared to the failed (PH3) batch (Table 21); however no statistical difference 
was observed in the abundance of the flagellin protein.  
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Table 19: Serovar Copenhageni proteins detected in a passed batch (PH1) of vaccine C.  
Accession  Protein  Primary Protein Protein Length  Mean No.  Mean  Mean  
Number identification Function (Amino Acids) of peptides % Coverage ln(NSAF)* 
45656175 Cell Wall Hydrolase Hydrolase activity  221 17.33 3 -1.97 
45658793 LipL41 Binding  355 14.33 32.33 -2.65 
45655648 Acyl Carrier Protein Transporter activity 77 3 16.33 -2.71 
45657230 LipL32 Unknown 272 9 21.33 -2.83 
45657213 Chaperonin GroEL Nucleotide binding 546 12.33 22 -3.22 
45657102 Peroxiredoxin Antioxidant activity 193 3.67 9 -3.4 
45658988 
Hypothetical 
Protein 
LIC13166 
Unknown 306 5 15.33 -3.54 
45657748 Putative Lipoprotein Unknown 412 5.67 16 -3.78 
45657753 Flagellin Protein Structural molecule activity  281 3.67 9.33 -3.79 
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45656504 DNA-Binding Stress Protein Ion binding 172 2.33 13.33 -3.88 
45656611 Putative Lipoprotein Unknown 440 5 9.33 -3.94 
45657078 Putative Citrate Lyase Catalytic activity 330 3.67 18.67 -3.95 
45656816 Putative Lipoprotein Unknown 497 4.33 10 -4.17 
45657930 Cysteine Synthase Catalytic activity 309 2.33 7 -4.33 
45658246 
Isoleucyl-
tRNA 
Synthetase 
Catalytic activity 914 6 2 -4.46 
45657869 
ATP-
Dependent 
Protease 
Nucleotide binding 860 5 1 -4.58 
45657309 
Histidine 
Kinase Sensor 
Protein 
Nucleotide binding 489 2 1 -4.92 
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45658253 
Putative 
Glutamine 
Synthetase 
Protein 
Catalytic activity 473 2 3.67 -4.98 
45657926 
Hypothetical 
Protein 
LIC12078 
Catalytic activity 525 2 1 -5.09 
45658471 
Hypothetical 
Protein 
LIC12634 
Binding  1125 2.33 0.33 -5.62 
45656945 Cell Division Protein Nucleic acid binding 948 2 0.33 -5.68 
45656648 
DNA-Directed 
RNA 
Polymerase 
Subunit Beta' 
Transferase activity 1404 2 1.33 -5.98 
Total Conserved Proteins 22 
*Higher ln(NSAF) values indicate greater abundance. 
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Table 20: Serovar Copenhageni proteins detected in a failed batch (PH3) of vaccine C.  
Accession  Protein  Primary Protein Protein Length  Mean No.  Mean  Mean  
Number identification Function (Amino Acids) of peptides % Coverage ln(NSAF)* 
45656175 Cell Wall Hydrolase Hydrolase activity  221 13.67 3 -1.88 
45655648 Acyl Carrier Protein Transporter activity 77 3 20 -2.36 
45658793 LipL41 Binding  355 12.33 31.33 -2.44 
45657230 LipL32 Unknown 272 5 16.33 -3.07 
45657213 Chaperonin GroEL Nucleotide binding 546 7.67 15.33 -3.35 
45656611 Putative Lipoprotein Unknown 440 4.67 9 -3.63 
45657043 Dihydrolipoamide Dehydrogenase Oxidoreductase activity  490 5 2.67 -3.67 
45658988 Hypothetical Protein LIC13166 Unknown 306 3 10 -3.7 
45658246 Isoleucyl-tRNA Synthetase Catalytic activity 914 7.67 2 -3.89 
45657078 Putative Citrate Lyase Catalytic activity 330 2.67 15.33 -3.91 
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45657753 Flagellin Protein Structural molecule activity  281 2 6.67 -4.12 
45657748 Putative Lipoprotein Unknown 412 2.33 5 -4.27 
45657309 Histidine Kinase Sensor Protein Nucleotide binding 489 2 1 -4.57 
45657022 Hypothetical Protein LIC11138 Unknown 501 2 1 -4.6 
45657869 ATP-Dependent Protease Nucleotide binding 860 3 1 -4.73 
45656046 
ABC Transporter 
ATP-Binding 
Protein 
Nucleotide binding 606 2 1 -4.79 
45655920 DNA Gyrase Subunit A Nucleic acid binding 834 2 1 -5.11 
45656945 Cell Division Protein Nucleic acid binding 948 2 0 -5.24 
Total Conserved Proteins 18 
*Higher ln(NSAF) values indicate greater abundance. 
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Table 21: Abundance of conserved serovar Copenhageni proteins present in a passed (PH1) and failed (PH3) batch of vaccine C.  
Accession  Protein  Primary Protein Relative Protein Abundance (Mean ln(NSAF))* 
Number identification Function Passed Failed 
P Value 
45657309 Histidine Kinase Sensor Protein Nucleotide binding -4.92 (1) -4.57 (1) 9.23E-03 
45657230 LipL32 Unknown -2.83 (21) -3.07 (16) 3.20E-02 
45658246 Isoleucyl-tRNA Synthetase Catalytic activity -4.46 (2) -3.89 (2) 8.58E-02 
45658988 Hypothetical Protein LIC13166 Unknown -3.54 (15) -3.70 (10) 9.39E-02 
45656611 Putative Lipoprotein Unknown -3.94 (9) -3.63 (9) 1.05E-01 
45657748 Putative Lipoprotein Unknown -3.78 (16) -4.27 (5) 1.70E-01 
45658793 LipL41 Binding  -2.65 (32) -2.44 (31) 1.90E-01 
45656945 Cell Division Protein Nucleic acid binding -5.68 (0) -5.24 (0) 2.04E-01 
45657213 Chaperonin GroEL Nucleotide binding -3.22 (22) -3.35 (15) 3.63E-01 
45655648 Acyl Carrier Protein Transporter activity -2.71 (16) -2.36 (20) 3.65E-01 
45657869 ATP-Dependent Protease Nucleotide binding -4.58 (1) -4.73 (1) 3.83E-01 
45657753 Flagellin Protein Structural molecule activity  -3.79 (9) -4.12 (7) 4.66E-01 
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45656175 Cell Wall Hydrolase Hydrolase activity  -1.97 (3) -1.88 (3) 5.42E-01 
45657078 Putative Citrate Lyase Catalytic activity -3.95 (19) -3.91 (15) 8.55E-01 
Total Conserved Proteins 22 18   
*Higher ln(NSAF) values indicate greater abundance. Figures in brackets represent mean percentage protein coverage 
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4.2.4 Quantitation of LipL32 in passed and failed batches of vaccine 
Quantification of LipL32 in batches of vaccine C was determined using multiple 
reaction monitoring (MRM) mass spectrometry (section 2.5.5). Four tryptic peptides, 
identified as corresponding to LipL32 in serovar Canicola (section 4.2.2; Table 22) and 
vaccine C (section 4.2.3; Table 22), were chosen for quantitation; the full sequence of 
LipL32 and the relative positions of the tryptic peptides selected are shown below table 
22. A number of different MRM transition states for these tryptic peptides were derived 
(Table 23) from the MS and MS/MS data acquired through previous 2D-LC/MS 
analysis of serovar Canicola (section 4.2.2); Masshunter (Agilent) was used to 
automatically determine which of these were optimal (Table 24). 
 
Table 22: Comparison of LipL32 tryptic peptides detected in serovar Canicola protein extracts and 
two batches of vaccine C (PH1 and PH3).  
Peptide  Passed  Failed 
Sequence 
Serovar 
Canicola Vaccine  Vaccine 
SSFVLSEDTIPGTNETVK + + - 
AYYLYVWIPAVIAEMGVR + - - 
MISPTGEIGEPGDGDLVSDAFK + - - 
SMPHWFDTWIR + + + 
MSAIMPDQIAK + + + 
LDDDDDGDDTYK + - - 
IKIPNPPK + - - 
IPNPPK + - - 
ISFTTYKPGEVK + - + 
Note: + or – indicates the presence or absence of the tryptic peptide respectively. The full amino 
acid sequence of LipL32 and the locations of the tryptic peptides used for quantitation (grey) are 
shown below. The signal peptide is shown in red. 
MKKLSILAISVALFASITACGAFGGLPSLKSSFVLSEDTIPGTNETVKTLLPYGSV
INYYGYVKPGQAPDGLVDGNKKAYYLYVWIPAVIAEMGVRMISPTGEIGEPGD
GDLVSDAFKAATPEEKSMPHWFDTWIRVERMSAIMPDQIAKAAKAKPVQKLD
DDDDGDDTYKEERHNKYNSLTRIKIPNPPKSFDDLKNIDTKKLLVRGLYRISFTT
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YKPGEVKGSFVASVGLLFPPGIPGVSPLIHSNPEELQKQAIAAEESLKKAASDAT
K  
 
Table 23: MRM transitions identified from the MS/MS analysis of the LipL32 tryptic peptides of 
interest.  
Precursor ion Product ion  Collision  
Peptide Sequence 
 for MRM 
(m/z) 
 for MRM 
(m/z) Energy (V) 
457.30 529.30 12 
457.30 585.30 12 
457.30 628.80 12 
685.60 585.30 23 
685.60 820.50 23 
ISFTTYKPGEVK 
685.60 1022.60 23 
962.50 421.20 30 
962.50 845.40 35 
962.50 1061.50 23 SSFVLSEDTIPGTNETVK 
962.50 1390.70 30 
493.50 235.10 13 
493.50 629.80 13 
493.50 1024.50 13 
738.30 235.10 23 
738.30 629.30 23 
SMPHWFDTWIR 
738.30 1024.50 23 
706.30 662.30 15 
706.30 775.40 15 
706.30 1042.60 15 
1058.80 773.40 28 
1058.80 1042.60 28 
AYYLYVWIPAVIAEMGVR 
1058.80 1342.70 28 
Note: Collision energies calculated automatically by Masshunter (Agilent). 
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Table 24: Tryptic peptides and product ions selected for detection and quantification of LipL32 using multiple reaction monitoring (LC-MRM). 
Position from Molecular Mass  Precursor ion Product ion  Retention Time  
Number Peptide Sequence 
 N Terminus (Da)  for MRM (m/z)  for MRM (m/z) (min) 
1 ISFTTYKPGEVK 212-223 1369.56 457.3 628.8 10.8 
2 SSFVLSEDTIPGTNETVK 31-48 1924.07 962.5 845.4 13.16 
3 SMPHWFDTWIR 126-136 1475.671 738.3 1024.5 13.301 
4 AYYLYVWIPAVIAEMGVR 79-96 2114.516 706.3 1042.6 20.709 
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Calibration curves for all four tryptic peptides were constructed using Graphpad Prism 4 
over the tested concentration range (0.01-100 fmol; Figure 17). Total ion 
chromatograms of the four tryptic peptides at the different concentrations are shown in 
figure 18. Tryptic peptides 3 and 4 were excluded from further analyses due to the low 
response rates observed in figures 15 and 16. 
 
 The LOD of tryptic peptides 1 and 2 was determined (section 2.1)  as 0.018 and 0.025 
fmol\µg respectively, whereas the LOQ were  0.05 and 0.02 fmol\µg respectively.  
 
Batches of vaccine C that had passed (PH1 and PH2) and failed (PH3 and PH4) the 
hamster challenge test (Table 18), when tested against serovar Canicola, were subjected 
to MRM quantification. Initial analysis of the resulting chromatograms (Figure 19) 
showed that there was substantially less of the N terminus region of LipL32 in the failed 
batches than was present in the passed. 
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Figure 17: Linear regression of synthetic LipL32 peptides 1-4 (Table 24) standards using MRM.  
Note: Two replicates of each standard were used for each concentration; mean and standard error of the mean are shown. Response is an arbitrary measure used by 
Masshunter (Agilent) and has no unit of measurement 
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Figure 18: Total ion chromatograms (TIC) of synthetic LipL32 tryptic peptides used as calibration 
standards detected on a QQQ mass spectrometer.  
Note: Peak numbers correspond to peptide sequences shown in Table 24. 
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Figure 19: MRM chromatogram of passed (shown in blue) and failed (shown in red) batches of vaccine C.  
Note: Transition selected on left is for the C terminus of the protein (Peptide 1; Table 24) and transition selected on right is for the N terminus (Peptide 2; Table 24). 
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Accurate determination of the concentration of the selected C and N terminal peptides 
in each vaccine batch was achieved through interpolation with the synthetic peptide 
calibration curve (Figure 17) using Masshunter (Agilent). The results presented herein 
clearly show that the concentration of the selected LipL32 N terminus peptide was 
significantly lower (p ≤ 0.01) in vaccine batches that failed against serovar Canicola 
(n=2; Table 25) compared to the same LipL32 peptide in batches that passed against 
both serovars (n=2); no statistical difference was observed in the concentration of the 
peptide selected to represent the C terminus region. A vaccine batch that had passed 
against serovar Canicola but failed against Icterohaemorrhagiae (PH5) was selected to 
act as a control and the selected peptides were quantified for this sample (Table 25); a 
decrease in the concentration of the selected LipL32 N terminus peptide was not 
observed suggesting this to be specific to batches that fail against Canicola. Vaccines A, 
B, D and E were also analysed using the selected peptides to provide a point of 
comparison against vaccine C (Table 25); all four vaccines showed substantially 
decreased concentrations of the selected LipL32 N terminus peptide compared to that 
observed in batches PH1 and PH2 of vaccine C. 
 
Table 25: Concentration of the C and N terminus tryptic peptides (peptides 1 and 2) of LipL32 in 
vaccines A-E.  
Vaccine Concentration (fmol/µg); Mean ± 1 SD) Vaccine  
C Terminus N Terminus 
P Value 
A 26.04 ± 5.56 0.10 ± 0.02 0.0149 
B 39.40 ± 5.86 0.18 ± 0.01 0.0073 
C- PH1* 1.14 ± 0.07 1.73 ± 0.71 0.2989 
C- PH2* 0.62 ± 0.12 0.83 ± 0.19 0.1043 
C- PH3 0.59 ± 0.06 0.06 ± 0.01 0.0051 
C- PH4 1.00 ± 0.02 0.10 ± 0.01 0.0001 
C- PH5 0.98 ± 0.08 2.27 ± 0.23 0.0103 
D 2.43 ± 0.12 0.04 ± 0.02 0.0009 
E 30.31 ± 1.99 0.12 ± 0.03 0.0015 
Note: Three replicates of each batch were analysed. Passed batches denoted by * 
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4.3 Discussion 
Proteomic analysis of serovar Canicola identified 1015 Leptospira proteins when 
searched against a serovar Copenhageni database; this represents a substantial 
improvement in coverage over the serovar Copenhageni and Pomona proteomes 
previously determined by Eshgi et al (2008) and Vieira et al (2009) respectively (Table 
17). Whilst the studies performed by Malmstrom (2009), Cao (2010) and Zhong (2011) 
all identified a larger number of proteins (Table 17) it is important to note that all of 
these studies benefited from a species specific protein database which is currently 
unavailable for serovar Canicola; in addition the studies by Malmstrom (2009) and Cao 
(2010) did not report the use of biological replicates. Annotation of the serovar Canicola 
proteome (Figure 15) revealed that the proteins identified were representative of a large 
range of biological functions indicating that protein extraction (and resulting analysis) 
had not selectively favoured specific cellular components. More importantly 2D-LC-
MS/MS analysis of serovar Canicola revealed which peptides, corresponding to 
Leptospira proteins, could be identified using this technique allowing a subsequent 
comparison (Table 22) which was used when choosing which peptides to quantify in the 
vaccines using MRM. 
 
Initial estimation of the protein abundance of conserved proteins in passed and failed 
batches of vaccine C were performed using spectral counting (NSAF). The results 
achieved indicated that two proteins, LipL32 and Histidine Kinase Sensor protein, were 
present at a statistically (p≤ 0.05) higher relative abundance in the passed batches 
compared to the failed (Table 21). The low spectral abundance (NSAF score) of LipL32 
in failed batches of vaccine C and the previously identified conservation of this protein 
in all vaccines tested (A-E; Chapter 3) suggested that this would be a good candidate 
protein for further investigation using a more quantitative approach (Ong and Mann, 
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2005); conversely the absence of Histidine Kinase Sensor Protein from the protein 
consensus of vaccines A-E (Chapter 3) suggest it to be a poor biomarker and so was 
excluded from further analysis. Multiple reaction monitoring (MRM), which quantitates 
proteins based on the mass detection of specific peptide sequences, was chosen as a 
quantification method due to its high sensitivity and specificity (Lange et al., 2008) and 
to ensure good coverage of LipL32 two peptide sequences, corresponding to the start (N 
terminus) and end (C terminus) of the protein, were selected for quantitation (section 
2.5.5). The concentration of the C terminus peptides was approximately the same across 
PH1-PH4 (p≤0.7; Table 25); in contrast the concentration of the N terminus peptide was 
substantially lower (p≤0.01; Table 25) in batches that failed against serovar Canicola 
(PH3-PH4). This may be an indication that alteration of the LipL32 N terminus has 
taken place in batches of vaccine C that failed the in vivo potency test (when challenged 
against Canicola), the result of which is a detectable change in abundance of a specific 
N terminal peptide; whereas the C terminal peptide (extracted and quantified in the 
same experiment) remains relatively unchanged between sample sets. Interestingly, no 
decrease in the concentration of the same N terminal LipL32 peptide was observed in a 
vaccine batch (PH5) that failed when challenged against serovar Icterohaemorrhagiae 
(but passed against Canicola). While this suggests that the LipL32 N terminal truncation 
occurs in a serovar specific manner a far larger sample cohort is required to gain 
statistically relevant confirmation of these findings. However it is plausible to suggest 
that N terminal quantification of LipL32 could be used as a specific potency test for 
vaccine C.  
 
It is interesting to note that substantially decreased concentrations of the N terminal 
LipL32 peptide, compared to the C terminal LipL32 peptide (p≤0.01), were observed in 
vaccines A, B, D and E. However failed batches of these vaccines were not available for 
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analysis, as the manufacturers were unwilling to release them due to their commercial 
sensitivity, making it impossible to do a proper comparison of the N and C terminal 
LipL32 peptides from different vaccines and batches. It is conceivable that lower levels 
of the N terminal LipL32 peptide in these vaccines is sufficient to elicit an immune 
response due to the presence of more efficacious adjuvants; likewise it is possible that 
other components of these vaccines (such as protein or LPS) could be having an 
immunostimulatory effect. Further analysis of passed and failed batches of these 
vaccines is required to determine if N terminal quantification of LipL32 could be 
applied to them as an in vitro potency test. 
 
In contrast to the results achieved herein, a previous study (Hauk et al., 2008) identified 
the primary immunogenic domain of LipL32 as its C terminus region. Using a 
recombinant protein Hauk et al showed that a representative peptide of the N terminus 
of LipL32 did not react against antibodies raised in mice or humans (the N and C 
terminus regions used by Hauk et al encompass the N and C terminal LipL32 peptides 
used for quantification in this study). However there is insufficient evidence given that 
the mice and human sera contained protective antibodies against Leptospira as the mice 
used were not challenged with Leptospira after inoculation and there is no mention of 
the humans being vaccinated or having recovered without medical intervention (i.e. 
antibiotics). Therefore the study by Hauk et al may not accurately represent how LipL32 
is recognised in vivo explaining the disparity found with this work. Interestingly two 
synthetic LipL32 peptides (AAKAKPVQKLDDDDDGDDTYKEERHNK and 
LTRIKIPNPPKSFDDLKNIDTKKL) have been previously identified (Lottersberger et 
al., 2009) as being highly immunogenic against serovars Copenhageni and 
Icterohaemorrhagiae. However as these sequences are located between the N and C 
LipL32 peptides used for quantitation in this study, and the additional two LipL32 
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peptides assessed (AYYLYVWIPAVIAEMGVR  and SMPHWFDTWIR) could not be 
quantitated, it is impossible to ascertain if they were present in the failed batches of 
vaccines. 
 
It is also conceivable that the role of the N terminus in stimulating protective antibodies 
is more indirect and consequently it may not be able to stimulate an immune response 
on its own. The crystal structure of LipL32 (Vivian et al., 2009) reveals that the N 
terminus region in question forms a β- hairpin structure which, when viewed in three 
dimensions, appears to wrap around the middle region of the protein. It is possible that 
the presence of the N terminus region of LipL32 confers conformational stability to the 
structure of the whole protein such that the antibody representing motif is recognised by 
the immune system resulting in the generation of protective antibodies. Thus any 
disruption of the LipL32 tertiary structure would impact on the ability of the protein to 
elicit an immune response preventing the generation of protective antibodies, as seen in 
batches that fail against serovar Canicola.  
 
In conclusion this study has used 2D-LC-MS/MS, in conjunction with spectral counting, 
to identify LipL32 as a potential biomarker for potency in serovar Canicola vaccines. 
Further it has been shown that MRM based quantitation of specific N terminal peptides 
has the potential to act as a novel assay target for the determination of potency in vitro. 
Thorough detailed validation of this assay will require access to a larger sample cohort 
of passed and failed batches from multiple manufacturers to determine if it can replace 
the hamster challenge batch potency test.  
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Chapter 5  Evaluation of the immunoprotective effects of 
LipL32 against Leptospira interrogans serovar Canicola in 
Hamsters 
5.1 Introduction 
Our previous studies (Chapter 4) proposed that N terminal quantitation of LipL32 could 
be an effective in vitro biomarker assay for the determination of vaccine potency. 
However due to the commercially sensitive nature of the vaccines further passed and 
failed batches were unavailable, preventing more thorough validation of this assay. This 
chapter focuses on the evaluation of the protective effects of LipL32 (purified from a 
recombinant E. Coli expression system; section 2.6.5) against Leptospira interrogans 
serovar Canicola in the hamster model to determine if LipL32 is a suitable vaccine 
candidate. The primary aim was to test the hypothesis that LipL32 is a suitable vaccine 
candidate. This would be an important step in establishing if the shortening of LipL32 
observed in failed vaccine batches (Chapter 4) was responsible for the inability of the 
failed vaccines to confer immunological protection following challenge with L. 
interrogans serovar Canicola. 
 
5.2 Results 
5.2.1 Genetic analysis of LipL32 from Leptospira interrogans serovar Canicola 
strain Kito 
A highly virulent strain (Silva et al., 2008) of Leptospira interrogans serovar Canicola 
(strain Kito) was chosen as the challenge strain in this study. The gene sequence of 
LipL32, derived using DNA from strain Kito, was therefore determined (section 2.6.3) 
to ascertain commonalities with other serovar Canicola strains in the literature. The 
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resulting nucleotide sequence was translated into an amino acid sequence using 
Lasergene (DNASTAR Inc, USA) and compared (section 2.6.3) against three complete 
LipL32 sequences, from strains Hond Utrecht IV (GI: 33589193), RTCC 2805 (GI: 
358357257) and Lin (GI: 48526297) (Figure 20). 
 
The in silico translated amino acid sequence of strain Kito was identical to strain Lin 
(Figure 20). The sequence was highly conserved (compared to strains Kito and Lin) 
across strains RTCC 2805 and Hond Utrecht IV, each having only one amino acid 
substitution (at positions 73 and 165 respectively). The substitution of the amino acid 
valine for alanine, in strain RTCC 2805, is unlikely to represent a major structural 
change in the protein due to the shared chemical structure and properties of the two 
amino acid residues (both being non polar aliphatic compounds). The substitution of 
aspartic acid for asparagine in strain Hond Utrecht IV represents a similarly minor 
chemical change although a change in amino acid charge state would also occur. 
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MKKL SI L AI SVAL FASI TACGAFGGL PSL KSSFVL SEDTI PGTNETVKTL L PYGSVI NYYGYVKPGQAPD 70Kito
MKKL SI L AI SVAL FASI TACGAFGGL PSL KSSFVL SEDTI PGTNETVKTL L PYGSVI NYYGYVKPGQAPD 70Hond_Utrecht_IV
MKKL SI L AI SVAL FASI TACGAFGGL PSL KSSFVL SEDTI PGTNETVKTL L PYGSVI NYYGYVKPGQAPD 70RTCC_2805
MKKL SI L AI SVAL FASI TACGAFGGL PSL KSSFVL SEDTI PGTNETVKTL L PYGSVI NYYGYVKPGQAPD 70Lin
GL VDGNKKAYYL YVWI PAVI AEMGVRMI SPTGEI GEPGDGDL VSDAFKAATPEEKSMPHWFDTWI RVERM 140Kito
GL VDGNKKAYYL YVWI PAVI AEMGVRMI SPTGEI GEPGDGDL VSDAFKAATPEEKSMPHWFDTWI RVERM 140Hond_Utrecht_IV
GL ADGNKKAYYL YVWI PAVI AEMGVRMI SPTGEI GEPGDGDL VSDAFKAATPEEKSMPHWFDTWI RVERM 140RTCC_2805
GL VDGNKKAYYL YVWI PAVI AEMGVRMI SPTGEI GEPGDGDL VSDAFKAATPEEKSMPHWFDTWI RVERM 140Lin
SAI MPDQI AKAAKAKPVQKL DDDDDGDDTYKEERHNKYNSL TRI KI PNPPKSFDDL KNI DTKKL L VRGL Y 210Kito
SAI MPDQI AKAAKAKPVQKL DDDDNGDDTYKEERHNKYNSL TRI KI PNPPKSFDDL KNI DTKKL L VRGL Y 210Hond_Utrecht_IV
SAI MPDQI AKAAKAKPVQKL DDDDDGDDTYKEERHNKYNSL TRI KI PNPPKSFDDL KNI DTKKL L VRGL Y 210RTCC_2805
SAI MPDQI AKAAKAKPVQKL DDDDDGDDTYKEERHNKYNSL TRI KI PNPPKSFDDL KNI DTKKL L VRGL Y 210Lin
RI SFTTYKPGEVKGSFVASVGL L FPPGI PGVSPL I HSNPEEL QKQAI AAEESL KKAASDATK 273Kito
RI SFTTYKPGEVKGSFVASVGL L FPPGI PGVSPL I HSNPEEL QKQAI AAEESL KKAASDATK 273Hond_Utrecht_IV
RI SFTTYKPGEVKGSFVASVGL L FPPGI PGVSPL I HSNPEEL QKQAI AAEESL KKAASDATK 273RTCC_2805
RI SFTTYKPGEVKGSFVASVGL L FPPGI PGVSPL I HSNPEEL QKQAI AAEESL KKAASDATK 273Lin
Strain  Amino Acid Sequence Sequence No.
 
Figure 20: Sequence comparison of LipL32 from serovar Canicola strain Kito (characterised in this study) with LipL32 genes from other serovar Canicola strains found in 
the literature.  
Note: Amino acid sequences shown are predicted from the nucleotide sequence; differences are highlighted in yellow. 
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5.2.2 Construction of a recombinant E. coli strain to express LipL32 protein 
The LipL32 gene from serovar Canicola strain Kito was subsequently cloned (section 
2.6.4) into a pRSET C vector, downstream from a polyhistidine tag and T7 expression 
promotor (Figure 21). 
 
pRSETC_LipL32
3734 bp
EcoRI
KpnI
Primer 7
LipL32
Primer 9
f1 Ori
Ampicillin
pUC Ori
PT7
6xHis
 
Figure 21: Plasmid schematic of pRSET C following insertion of LipL32 gene.  
Note: Promotor (T7), Polyhistidine tag (6xHis) and primers used to confirm insertion shown in 
blue; KpnI and EcoRI restriction sites used to insert LipL32 gene are also shown. 
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Transformation into the E. coli expression strain BL21(DE3)pLysS (containing a 
chloramphenicol resistance gene) of the resultant recombinant vector, termed 
pRSETC_LipL32, was achieved chemically (section 2.6.4) resulting in an IPTG 
inducible expression strain. Successful transformants were screened using selective 
media (containing 50 µg/ml ampicillin and 35 µg/ml chloramphenicol; section 2.3.2) 
and polymerase chain reaction (PCR) was used to confirm the presence and orientation 
of the LipL32 gene within the strain (Figure 22). 
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Figure 22: PCR of recombinant LipL32 expression strain (Lane 2) using primers 7 and 9 (Table 7) 
run on a 1% agarose gel.  
Note: Lanes 1 and 4 contain a 1Kb ladder and lane 3 contains a negative control reaction without 
DNA. 
 
Primers 7 and 9 (Table 7) were selected for PCR as they bind to the LipL32 gene 
(insert) and pRSET C (vector) respectively; a band approximately corresponding to the 
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predicted PCR product (922 base pairs) was observed following gel electrophoresis 
(Figure 22). 
 
5.2.3 Purification of expressed LipL32 protein 
Expression of LipL32 from the recombinant pRSETC_LipL32 E. coli strain was 
induced using IPTG (2 mM; section 2.6.5) and the resulting His tagged LipL32 protein 
was purified using nickel magnetic beads (section 2.6.5). The total protein contents of 
the purified LipL32 protein, and a passed vaccine (Vaccine F; positive control for 
subsequent in vivo experiments), were estimated using the Bradford assay and a 
nanodrop (280 nm; section 2.3.7) respectively; assay derived differences in protein 
concentration did not affect the final in vivo experiment as all samples were subjected to 
MRM quantitation prior to use. The LPS content of the purified protein and passed 
vaccine was determined using the LAL assay (Table 26) as previously described 
(section 2.4.3).  
 
Table 26: Concentration of LipL32 (N and C termini using MRM), total protein and LPS in 
recombinant LipL32 protein and Vaccine F. 
Concentration Concentration of LipL32 
(Mean ± 1 SD) (fmol/µg); Mean ± 1 SD 
 
Protein 
(mg/ml) 
LPS 
(µg/ml) C Terminus N Terminus 
Vaccine F 9.69±0.40 0.01±0.00 1.07±0.22 2.65±1.09 
LipL32 21.75±0.49 0.47±0.01 3096.17±1449.91 7130.33±2649.79 
 
As QQQ mass spectrometers are known to be more accurate, compared to a Q-ToF, for 
the analysis of small molecules (Wolf-Yadlin et al., 2007), MRM mass spectrometry 
was used to analyse (section 2.5.5) the C and N termini of LipL32 in the recombinant 
protein and passed vaccine. Since the selected peptides, and their MRM transitions, are 
specific to LipL32 this allowed accurate identification and quantitation of the protein in 
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a single experiment. Gel electrophoresis (Figure 23) of the purified LipL32 protein 
(10µg; 71.3 pmol, N terminus) with Coomassie staining, showed one band at the 
predicted size of mature length LipL32 (27.8 kDa).  At this level of sensitivity the 
absence of additional bands indicated that, within the detection range of the stain (≥ 5 
ng of protein; Fisher, UK), no other proteins were detected. 
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Figure 23: Purified LipL32 protein (Lane 2; 10µg) run on a 4-12% NUPAGE gel stained with 
Coomassie blue to detect protein.  
Note: Lanes 1 and 3 contain a 3.5 - 260 kDa protein ladder. 
 
5.2.4 Assessment of the protective effect of recombinant LipL32 in the hamster 
vaccine batch potency test model 
The hamster vaccine batch potency test (section 2.4.2) was used to determine the 
protective effect of recombinant LipL32 against L. interrogans serovar Canicola. Six 
groups of hamsters (n=5/group) were used, each receiving a different treatment (Table 
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27); group 6, as a negative control, comprised of less hamsters (n=3) to reduce animal 
use. Treatment groups 1 and 2 comprised of recombinant LipL32 +/- adjuvant 
respectively to explore the potential adjuvant effects on efficacy; each group (1 and 2) 
received 868.43 pmol/hamster of N terminal LipL32 (section 2.6.5). Group 3, the 
positive control, comprised of a potent vaccine (vaccine F; Table 27), diluted 1/40 with 
saline (as described in the details for the potency test, section 2.4.2) representative of a 
final N terminal LipL32 concentration of 0.64 pmol/hamster. Groups 4-6 (Table 27) 
comprised of negative controls to confirm, respectively, that the saline diluent used had 
no effect (group 4), that the challenge used was appropriately virulent (group 5) and that 
the stock of hamsters used were otherwise healthy (in addition to providing tissues for 
histological analysis; group 6; section 2.7.4). 
 
Table 27: Treatments protocols applied to hamster groups 1-6 (n=5) and number of survivors.  
Group Treatment Survivors P value 
1 LipL32 (no adjuvant) + challenge 1/5 1.000 
2 LipL32 + adjuvant + challenge 1/5 1.000 
3 Vaccine F + challenge 4/5 0.048 
4 Saline + challenge 0/5 ND 
5 No treatment + challenge 0/5 1.000 
6 No treatment + No challenge 3/3 0.018 
Note: Group 6 comprised of 3 hamsters. P values are 2 sided and obtained through comparison 
with the negative control (group 4) using Fisher’s exact test; ND indicates not determined. 
 
Following challenge with virulent L. interrogans serovar Canicola hamsters were 
routinely monitored and their condition assessed as described previously (section 2.4.2). 
Groups 1 and 2 failed the vaccine potency test on days 10 and 12 respectively with 4/5 
hamsters (Figure 24) either succumbing to infection or having to be euthanased; one 
hamster from each group survived until the end of the test (day 24), however this was 
not statistically significant (Table 27). Group 3, the positive control, passed the vaccine 
potency test with 4/5 hamsters surviving until day 24 (p≤ 0.05). As expected the 
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negative control groups 4 and 5 failed the test, at days 11 and 10 respectively; none of 
these hamsters survived until the end of the test. The hamsters in group 6 survived to 
day 24 confirming that the hamsters were from healthy stock (p≤ 0.05). 
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Figure 24: Survival of hamsters (days) in treatment groups 1-6 following infection with virulent L. interrogans serovar Canicola.  
Note: Some hamsters were euthanased due to severe clinical conditions. 
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5.2.5 Assessment of circulating antibodies in hamsters following vaccination with 
recombinant LipL32 
Serum taken from hamsters at post mortem (section 2.7.2) was analysed by ELISA 
(section 2.7.5) to determine the presence of antibodies specific to recombinant LipL32 
and L. interrogans serovar Canicola (Figure 25). While animals were frequently 
monitored some hamsters succumbed to infection between monitoring points and were 
therefore excluded from ELISA analysis. Statistical comparison of ELISA results from 
groups 1-6 could therefore not be performed as serum could not be obtained from 
sufficient subjects of the negative controls (groups 4 and 5). Data gained from ELISA 
analysis was therefore not considered when assessing the effect of LipL32 in vivo and is 
only included herein to show diligence of the approach attempted. 
 
Groups 1 and 2 displayed a higher antibody response to LipL32 than the negative 
control groups 4-5 (Figure 25); however a corresponding increase in response to L. 
interrogans serovar Canicola was not indicated. Group 3 displayed a higher response to 
both LipL32 and L. interrogans serovar Canicola (Figure 25), compared to groups 4 and 
5. Group 6, which was not vaccinated or challenged (Figure 25), showed a higher 
response to LipL32 than groups 4 and 5; however this did not correspond to an 
increased response to L. interrogans serovar Canicola.  
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Figure 25: Antibody response of serum (1/100 dilution) derived from treatment groups 1-6 against recombinant LipL32 (left; 1 µg/ml total protein) and L. interrogans 
serovar Canicola (right; 5 µg/ml total protein). 
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5.2.6 Histopathological analysis of hamsters immunised with LipL32 
Variable degrees of diffuse tubulointerstitial nephritis, consistent with Leptospira 
infection, were observed in the hamsters that died (or were euthanised according to the 
clinical score sheet; section 2.4.2) following challenge with L. interrogans serovar 
Canicola. The histological changes consisted of minimal infiltration of the interstitial 
spaces with lymphocytic cells and the frequent presence of strongly eosinophilic hyaline 
casts in the lumen of tubules, associated with attenuation of tubular epithelial cells and 
nephrosis. Occasional tubules displayed a mixture of sloughed cells and leukocytes in 
their lumen.  
 
Renal lesions were scored (section 2.7.4) based on their severity from 0-4 (Figure 26) 
using a semiquantitative scoring system modified from Palaniappan et al (2006); one 
slide, containing approximately 100 nephrons, was assessed per animal. Lower scores 
were observed in groups 1, 3 and 6 (Table 28) compared to groups 2, 4 and 5 (Table 
28); treatment group 1, which comprised LipL32 without adjuvant, had a significantly 
lower score (p≤ 0.01) compared to the negative control (group 4). Only one survivor 
from group 3 (euthanised on day 24) showed evidence of renal pathology as a minute 
focal lesion; no lesions were observed in group 6. The presence and number of 
leptospires in the kidney, liver and spleen was assessed using Warthin-Starry stain 
(Figure 27) and tissues were stratified using a semiquantitative scoring system (Table 
28).   
 
 142 
Score 0
Score 1 Score 2
Score 3 Score 4
*
10 µm
10 µm
10 µm10 µm
10 µm
 
Figure 26: Scoring system used to assess major histopathological changes observed in hamster 
kidneys following infection with L. interrogans serovar Canicola.  
Note: The increase in the number of tubules with eosinophilic protein casts in the lumen (black 
arrows) and intratubular inflammatory infiltration (white arrow); eosinophilic material is also 
present in the uriniferus spaces of Bowman’s capsule (shown with *).  Tissues stained with 
hematoxylin and eosin (H&E) and imaged using a 200x magnification. 
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Table 28: Severity of renal lesions and invasion of Leptospira in hamster tissues determined through staining with H&E and Warthin and Starry respectively.  
Invasion of Leptospira Severity of Renal lesions 
Kidney Liver Spleen Treatment Group 
Mean ± 1 SD P Value Mean ± 1 SD P Value Mean ± 1 SD P Value Mean ± 1 SD P Value 
1 1.8±1.1 0.004 1.2±0.8 0.009 2.4±1.3 0.070 1.0±1.0 0.621 
2 2.6±1.5 0.374 2.0±1.4 0.189 1.6±1.8 0.034 1.0±1.0 0.621 
3 0.6±0.9 0.001 0.0±0.0 ND 0.0±0.0 ND 0.0±0.0 ND 
4 3.0±0.7 ND 3.0±0.0 ND 3.6±0.5 ND 1.2±0.45 ND 
5 2.6±0.5 0.178 2.8±0.4 0.374 2.8±1.6 0.242 1.2±0.84 1.000 
6 0.0±0.0 ND 0.0±0.0 ND 0.0±0.0 ND 0.0±0.0 ND 
Note: Scored using a semiquantitative scoring system modified from Palaniappan et al 2006 (Palaniappan et al., 2006). Mean and standard deviation of the mean for the 
observed scores are shown. P values obtained through comparison with the negative control (group 4) using a Student’s t-test; ND indicates not determined. 
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Figure 27: Visualisation of Leptospires in infected hamster tissues.  
Note: Leptospires are highlighted with black arrows. Tissues stained with Warthin and Starry and imaged using a 1000x magnification. 
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Leptospires, when present in the kidneys, could be observed in the interstitial spaces 
and tubular lumina in the renal cortex and occasionally in intravascular locations or 
glomeruli. A significantly lower (p≤ 0.01) score for Leptospira kidney invasion was 
observed (Table 28) in group 1 compared to the negative control (group 4); no 
leptospires were observed in groups 3 or 6. 
 
In addition to histological analysis of hamster kidneys at post mortem, culturing was 
also performed (section 2.3.2). Leptospires were not observed in kidney cultures of 
animals euthanased at day 24 (Figure 24; groups 1-3, 6), which is in agreement with the 
histological findings. No leptospires were observed, by histological staining, in the 
kidneys of the hamster from group 3 that died at day 17 (Figure 24); however 
confirmatory data could not be obtained for this animal using kidney culturing due to 
the detection of bacterial contamination during processing. 
 
All hamsters that died (or had to be euthanased) following challenge with Leptospira 
displayed hepatodystrophy and liver plate disarray, with loss of the normal hepatic 
sinusoid architecture and multifocal infiltration by lymphohistiocytic cells. Some rare 
areas of minute necrosis were observed in two animals from group 4; no hepatic lesions 
were observed in the hamster from group 3 that died at day 17. Groups 1 and 2 showed 
reduced liver invasion scores (2.4±1.3 and 1.6±1.8 respectively; Table 28) compared to 
group 4 (3.6±0.5) however only group 2 showed a significant (p≤0.05) difference. An 
example of the histophathological effects of Leptospira on hamster livers is shown in 
figure 28, where loss of normal structure of the tissue, disorganization of the hepatic 
cords and altered morphology/size of hepatocytes can be seen in the diseased state.  
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Figure 28: Histopathological changes to hamster liver following infection with Leptospira.  
Note: Tissues stained with hematoxylin and eosin (H&E) and imaged using a 200x magnification. 
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The spleen of animals that died (or had to be euthanased), following challenge with 
Leptospira, showed marked hypertrophy and hyperplasia of macrophages of splenic 
cords in red pulp in the diseased state (Figure 29). Very few leptospires could be 
observed in the red pulp of hamsters showing splenic pathology; no significant 
difference in splenic invasion was observed between groups (Table 28). 
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Figure 29: Histopathological changes to hamster spleen following infection with Leptospira.  
Note: Tissues stained with hematoxylin and eosin (H&E) and imaged using a 200x magnification. 
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5.3 Discussion 
Construction of a recombinant E. coli strain to express LipL32 was performed using a 
variation of the method developed by Haake (Haake et al., 2000). As noted by Haake 
processing of the LipL32 protein does not occur properly in E. coli therefore the first 19 
amino acids, the signal peptide, was deliberately excluded from the recombinant strain 
created. Since the signal peptide is cleaved during processing of the protein (Haake et 
al., 2000) its absence from the recombinant strain is unlikely to have an effect on the 
resulting conformation of the protein, although conformation may be different 
compared with Leptospira derived LipL32; further confirmatory work is required to 
ascertain the exact conformation of E. coli derived LipL32. Glycosylation has been 
previously established to have no effect on the immunogenicity of LipL32 (Hartwig et 
al., 2010) therefore the effect of protein glycosylation was not investigated herein. 
 
Although E. coli protein contaminants were not observed in the purified LipL32 protein, 
it is probable that some were present at levels below the detection limit of SDS-PAGE. 
However histological analysis of the recombinant LipL32 treated hamsters clearly 
established Leptospirosis as the cause of death, therefore any E. coli proteins present are 
not likely to have contributed significantly to the disease process. Similarly it can also 
be assumed that the comparatively high level of LPS (compared to vaccine F) observed 
in the recombinant LipL32 had no detrimental effects. The presence of E. coli proteins 
and/or LPS could however be providing an immunostimulatory effect, in a similar 
manner to an adjuvant. Whilst no evidence exists to support this assertion it should be 
taken into account when planning future experiments and additional controls used to 
discount it as a contributing factor. 
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As the vaccine batch potency test is the only test currently recognised for the 
assessment of vaccines against L. interrogans serovar Canicola it was used to determine 
the protective effect of LipL32. Insufficient quantities of vaccines A-E (analysed in 
chapters 3 and 4) were available at the time of performing this test therefore an 
additional passed vaccine (F) was obtained and utilised solely for the purpose of a 
positive control. The N terminal concentration of LipL32 in groups 1 and 2 was 
deliberately in excess of that calculated in vaccine F (group 3) to ensure a response; in 
depth experimental analysis with multiple concentrations of LipL32 was precluded by 
funding and time constraints. The precise constituents of each vaccine (A-F) were not 
revealed by manufacturers due to the commercial considerations, therefore the potential 
beneficial effects of specific adjuvants could not be tested alongside the recombinant 
LipL32 used in this study; however the adjuvant used in vaccine B, aluminium 
hydroxide, was accepted as a proxy for all testing. 
 
The recombinant LipL32 used in this study did not show statistically increased survival 
against L. interrogans serovar Canicola which is in agreement with a previous study 
(Lucas et al., 2011). Subsequent antibody analysis of the hamster’s blood, using 
ELISAs, was largely inconclusive as limited samples precluded in depth statistical 
analysis. However the response of groups 1 and 2 against LipL32 was predominantly 
either equal to or in excess of the response observed in group 3 confirming that an 
equivalent dosage of LipL32 had been administered. A decreased score of kidney 
invasion (p≤ 0.01) was observed in the groups treated with LipL32 (group 1) which 
corresponded to decreased scores of kidney lesions (p≤ 0.01); indicating that although 
LipL32 is unable to provide complete protection, it is still able to reduce the severity of 
infection in the hamsters. This is not in accord with Lucas et al (Lucas et al., 2011) who 
concluded that LipL32 in isolation was unable to stimulate protective immunity in 
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hamsters. However histological analysis was not performed in this study which may 
explain the discrepancy; it should also be noted that serovar Manilae was assessed in 
their study, instead of serovar Canicola. 
 
Interestingly group 2, which received adjuvant in conjunction with LipL32, did not 
show significantly decreased kidney invasion/lesions when compared with the negative 
control (group 4). It is impossible to definitively explain this without a larger study 
however it is conceivable that aluminium hydroxide is either not suitable for 
presentation of a single protein against L. interrogans serovar Canicola or requires a 
larger dosage to be noticeably effective. As the concentration of LipL32 in groups 1 and 
3 was approximately the same it is reasonable to assume that group 3 either contains 
additional components required to initiate protective immunity, or possesses an 
increased immunostimulatory effect (either through the use of an adjuvant or other 
naturally occurring bacterial components). A recent study (Grassmann et al., 2012) 
demonstrated that LipL32 could provide protective immunity against serovar 
Copenhageni in hamsters when coadministered with the B subunit of E. coli heat-labile 
enterotoxin (LTB) as an adjuvant. It is conceivable therefore that the immunogenic 
effect of LipL32 against serovar Canicola will also be increased through using LTB as 
an adjuvant. This chapter suggests that LipL32 may be the active component of the 
vaccines studied which would suggest that the approach for vaccine analysis used herein 
has successfully identified a potential potency biomarker for an in vitro test, confirming 
the main hypothesis of this study; further it would also suggest that LipL32 may be a 
suitable vaccine candidate confirming the chapter hypothesis. A larger study using a 
range of LipL32 concentrations, in conjunction with a range of adjuvants, is suggested 
to fully elucidate the role of LipL32 in the vaccines. In addition further hamster studies 
should consider increasing the number of hamsters used from five hamsters per group to 
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ten as it would increase the 80% power of the test to detect differences between the 
groups.  
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Chapter 6  General Discussion 
The hypothesis of this study was to determine if biochemical analysis could be used to 
identify and quantify the common component(s) of commercially available L. 
interrogans serovar Canicola vaccines. The primary objective of which was to identify 
biomarker(s) of efficacy, present in L. interrogans serovar Canicola vaccines, which 
may be suitable for the development of an in vitro vaccine batch potency test as an 
alternative to the current hamster challenge test. The initial approach investigated the 
potential for a LPS based biomarker, as it had been previously reported to be a 
protective immunogen (Koizumi and Watanabe, 2003) and to have potential 
applications as a vaccine candidate (Wang et al., 2007, Srikram et al., 2011). Further an 
ELISA based test of serovar Canicola vaccines had been previously developed using 
LPS specific monoclonal antibodies (Ruby, 1999). However our experimental findings 
(Chapter 3) showed that LPS was not present at detectable levels in vaccine C. This 
suggested that biomarkers derived from this bacterial component would (at this level of 
sensitivity) be unsuitable for the development of a universally applicable in vitro 
potency test. Proteins derived from L. interrogans have also been reported to be 
immunogenic (Sonrier et al., 2000) and a number of protein based vaccines have 
previously been tested (Seixas et al., 2007a, Yan et al., 2009, Yan et al., 2010). The 
potential application of Leptospira derived proteins as biomarker(s) of efficacy for 
serovar Canicola vaccines was therefore also investigated. A novel method for the 
characterisation of the protein content of serovar Canicola vaccines, using 2D-LC/MS, 
was therefore developed and used to analyse the same five commercially available 
serovar Canicola vaccines (Chapter 3). 
 
Although the use of proteomics for the analysis of L. interrogans serovar Canicola 
vaccines has not been previously reported in the literature, proteomic based approaches 
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for the analysis of non-Leptospira vaccines, such as meningococcal outer membrane 
vesicle (Vipond et al., 2005), Actinobacillus pleuropneumoniae (Buettner et al., 2011) 
and influenza vaccines (Creskey et al., 2010) have been described. Many proteomic 
vaccine studies, such as those performed for Brucella melitensis (Eschenbrenner et al., 
2002) and Neisseria meningitidis (Uli et al., 2006), characterise the bacterial strain used 
to create the vaccine rather than the final fully formulated product used in the host. This 
approach is aided by the absence of interfering agents, present in the final vaccine 
formulation, such as adjuvant and preservative. Therefore the protein content 
determined using this approach is not entirely representative of the final vaccine product 
as it does not take into account protein losses/modifications that may occur during the 
formulation process. ELISA based methods for vaccine analysis and determination of 
potency have also been described in certain vaccines, such as poliovirus (Rezapkin et 
al., 2005) and bovine virus diarrhoea (Pecora et al., 2009) vaccines. Although the 
ELISA approach is quick and relatively cheap it is highly sensitive to contaminants and 
requires previous knowledge of the active vaccine component responsible for protective 
immunity. 
 
The development of a 2D-LC/MS method for serovar Canicola vaccine analysis 
provides a more robust approach for the identification of protein biomarkers of efficacy, 
which could later be developed into an in vitro vaccine potency test, as it characterises 
the protein component of fully formulated vaccines. This allows for the identification of 
the precise subsets of bacterial proteins potentially available for presentation to the host 
immune system (referred herein as the vaccine proteome); such proteomes can be used 
to identify protein biomarkers of efficacy which, once validated, could be developed 
into an in vitro vaccine potency test. Proteomic analysis of serovar Canicola vaccines 
may confirm the presence, and therefore potential involvement, of previously described 
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immunogenic factors, such as LipL41 (Haake et al., 1999) and LipL32 (Haake et al., 
2000); subsequent quantitation of their abundance in the vaccines may consequently 
increase our current understanding of how these serovar Canicola vaccines provide 
protection. Known immunogenic proteins identified in the serovar Canicola vaccines 
(A-E) may be suitable for development into novel subunit or recombinant protein 
vaccines; although further confirmatory work in animal models would be required to 
confirm this. Additional uses for vaccine analysis using mass spectrometry can be 
envisaged for the quality assurance stage of vaccine manufacture to ensure production 
consistency and shelf life. This could determine if the vaccine proteome differs between 
batches and that, if known, protein(s) responsible for vaccine potency are present at 
appropriate concentrations. Finally it is entirely feasible to expect that the proteomic 
vaccine analysis method described herein will be applicable to the analysis of other non- 
Leptospira vaccines. This could be of particular benefit for the characterisation of 
Clostridium vaccines as their existing challenge vaccine batch potency test has been 
recently identified (Kulpa-Eddy et al., 2011) as being in need of replacement due to the 
severity, and large number of animals required, of the current test. 
 
Proteomic characterisation of pathogenic Leptospira interrogans serovars is not 
widespread and to date only serovars Copenhageni (Eshghi et al., 2009, Malmstrom et 
al., 2009), Pomona (Vieira et al., 2009) and Lai (Cao et al., 2010, Zhong et al., 2011b) 
have been characterised (Chapter 4). A variety of methodologies ranging from basic 2D 
PAGE/MALDI-ToF techniques (Vieira et al., 2009) to an advanced LTQ-Orbitrap 
based LC-MS/MS approach (Cao et al., 2010) have been employed. Whilst these 
previous studies are informative it is important to note that to date only 3 of the 230 
known pathogenic serovars (Adler et al., 2011) have been characterised, making 
generalisations about Leptospira interrogans problematic. As the main focus of this 
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study was the analysis of vaccines that provide protection against L. interrogans serovar 
Canicola it was considered important to determine the proteome of bacterial extracts of 
serovar Canicola to increase our understanding of the bacteria and provide a point of 
comparison for vaccine analysis. The proteome of serovar Canicola, described herein 
(Chapter 4), is believed to be the first to be reported for this serovar. 
 
By identifying 1015 proteins in serovar Canicola this study has confirmed that these 
proteins are being actively expressed in the bacteria, under the growth conditions and at 
the time point used. Comparison of the functional annotation of these 1015 confirmed 
proteins, with the protein content of other serovars, may increase our overall 
understanding of the pathogenicity of Leptospira. It is also conceivable that such 
proteomic comparison may reveal commonalities between serovars, allowing the 
identification of novel multi serovar drug and vaccine targets.  In addition unique 
serovar specific protein biomarkers may be identified which would allow the 
development of novel diagnostic tests, using techniques such as MRM or ELISA, for 
serovar differentiation. Due to the quantitative nature of these techniques it could be 
suggested that they may be more accurate than the existing serology based test (MAT). 
Such improved accuracy would improve determination of the epidemiology of 
Leptospira and aid in preventative treatment strategies such as vaccination (Pol et al., 
2009). Further optimisation of proteomic coverage may be achieved by selection of 
alternate growth conditions and/or protein extraction methods with associated further 
development of processing methods adopted herein. This could be considered in future 
studies to increase our understanding of how Leptospira responds to different 
environmental stimuli/stresses and increase the coverage of the serovar Canicola 
proteome. 
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In an analytical comparison of five serovar Canicola vaccine proteomes the outer 
membrane protein LipL32 was detected in all five vaccines analysed (Chapter 3). 
LipL32 had a lower relative spectral abundance in failed batches of vaccine C compared 
to passed batches (Chapter 4). Multiple reaction monitoring, which has a high 
sensitivity and specificity (Wolf-Yadlin et al., 2007), was subsequently used to 
quantitate the concentration of LipL32 in passed and failed batches of serovar Canicola 
vaccine (Chapter 4). This study is the first to apply 2D-LC/MS and MRM for biomarker 
discovery and quantitation in serovar Canicola vaccines; this approach could be 
successfully adapted for the analysis of other commercially available protein based 
killed vaccines. MRM quantitation of vaccines has a number of potential applications 
including, but not limited to, the development and/or improvement of in vitro vaccine 
potency tests; such as the aforementioned in vitro tests required for Clostridium 
vaccines. MRM analysis is a rapid analytical methodology with a high level of accuracy 
(Wolf-Yadlin et al., 2007), however it requires the use of synthetic peptides that match 
the protein/peptide of interest making it expensive thereby limiting its universal 
adoption. 
 
A link between reduced concentrations of N terminal LipL32 with a reduction in 
serovar Canicola vaccine potency (Chapter 4) was determined following MRM 
quantitation of serovar Canicola vaccine C. Although the structure of LipL32 has been 
determined (Vivian et al., 2009), and a previous study has suggested that the N termini 
does not have a direct involvement in the protective immune response (Hauk et al., 
2008), any indirect effect of the N terminus with the proteins conformational structure 
and immunogenicity has not been investigated. The results presented herein suggest that 
LipL32 may be a suitable target molecule for the development of an in vitro vaccine 
batch potency test for serovar Canicola which achieves the primary objective of this 
 158 
work. Proof of principle for such a test, using N terminal amino acid quantitation of 
LipL32, has also been demonstrated thereby achieving the secondary objective of this 
work. The identification of LipL32 as a biomarker for potency and the proof of 
principle for it’s used as part of an in vitro potency test answers the question of whether 
a protein potency biomarker can be identified in Leptospira interrogans serovar 
Canicola vaccines, raised in the hypothesis of this study. 
 
Methodologies developed herein may be applicable to other Leptospira serovars. 
However for accurate measurement of the potency of multivalent vaccines against 
specific serovars it would be advisable to choose different biomarkers for each serovar 
being assessed. N terminal LipL32 quantification of serovar Canicola vaccines using 
MRM represents a highly accurate potential replacement for the current hamster vaccine 
potency test. However vaccine quantification using mass spectrometry may not be the 
most practical test for widespread usage, particularly for smaller laboratories, due to the 
large commitment required in terms of equipment and expertise. An ELISA based in 
vitro potency test using N terminal LipL32 specific monoclonal antibodies may be more 
appropriate for widespread usage as it is cheaper to perform and less technically 
demanding. However as ELISAs are known to be highly sensitive to adjuvant 
contamination both approaches would need to be fully evaluated before the existing 
hamster vaccine potency test could be replaced. 
 
As additional failed batches of serovar Canicola vaccine were unavailable for analysis 
the use of N terminal quantitation of LipL32 as an in vitro potency assay could not be 
more extensively validated. Confirmatory evidence that LipL32 may be an active 
component of serovar Canicola vaccines was therefore sought by assessing the 
involvement of recombinant LipL32 in the protective immune response against L. 
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interrogans serovar Canicola in the hamster model. Recombinant LipL32 protein was 
extracted from an E. coli expression system using a modified version (Chapter 5) of the 
original method described by Haake (Haake et al., 2000). Comparison of the N and C 
termini of the recombinant LipL32 protein, against LipL32 derived from vaccines A-E, 
was achieved using MRM prior to its inoculation in the hamsters; the immunogenicity 
of the recombinant LipL32 protein was tested using ELISA with a polyclonal LipL32 
antibody. This study is the first to demonstrate that vaccination with low doses of 
recombinant LipL32 results in decreased kidney invasion of serovar Canicola and 
reduced lesion severity. Although complete immune protection was not observed this 
reduction of kidney invasion is indicative that LipL32 is involved in the immune 
response suggesting that the presence of LipL32 in serovar Canicola vaccines may be 
contributing to their potency and immunoprotection.  
 
Multiple studies into the usage of LipL32 as a vaccine candidate have been reported 
previously which have shown LipL32 to provide protection against serovars Canicola 
(Branger et al., 2005) and Copenhageni (Seixas et al., 2007a, Grassmann et al., 2012) 
but not against serovars Pomona (Cao et al., 2011) and Manilae (Lucas et al., 2011). 
The results presented herein provide further confirmatory evidence that LipL32 is 
involved in the protective immune response against serovar Canicola either on its own 
or in combination with other undetermined bacterial components. 
 
6.1 Future Work 
Prior to the existing hamster challenge vaccine potency test being replaced by an in 
vitro assay, such as N terminal LipL32 quantitation, approval will be required from the 
European pharmacopeia; obtaining such approval can be both time consuming and 
expensive. Further refinement and validation of the N terminal LipL32 quantitation 
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assay described must be performed, prior to it being submitted to the pharmacopeia for 
consideration, to increase its probability of gaining acceptance. Significant analysis of 
passed and failed vaccine batches, for every serovar Canicola vaccine currently 
available commercially, would therefore be required to enable statistical validation of 
the assay. In addition non serovar Canicola vaccine batches must be analysed to confirm 
that the reduction of N terminal LipL32 is specific to serovar Canicola vaccines. The 
inclusion of sequentially truncated N terminal LipL32 synthetic peptides in the MRM 
analysis of the vaccines could also be considered to determine the exact amino acid 
position that the protein has become modified. In addition the effect of N terminal 
LipL32 modification on the conformational structure of the protein could be 
investigated to ascertain how this differs from full length LipL32 and how differences 
may affect antibody binding. Refinement and validation of the LipL32 N terminal 
quantitation assay would require the cooperation of multiple vaccine manufacturers as 
well as a significant financial expenditure. The longer term benefits resulting from the 
implementation of an in vitro serovar Canicola vaccine potency test, such as a reduction 
in animal usage and concomitant costs, should therefore be carefully considered. 
 
Without further information from the vaccine manufacturer it is difficult to speculate as 
to why LipL32 has a reduced concentration of N terminal LipL32 in failed batches of 
vaccine C. Several possibilities are conceivable however including genetic mutation of 
the stock strain, physical/chemical modification of the protein during the manufacturing 
process and/or some form of structural protein instability leading to degradation over 
time. All of these factors need to be thoroughly investigated and, if possible, alterations 
to the vaccine manufacture process need to be made to reduce the incidence of this 
modification occurring. Development of a simplified vaccine, using a targeted series of 
peptides capable of eliciting a protective immune response, should also be considered; 
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as it would remove the requirement for bacterial culture, and the associated usage of 
animals to maintain strain virulence, requisite to create current vaccines. 
 
Whilst the work presented herein was comprehensive, within the remit of the study, it 
was not exhaustive and was necessarily limited by the technology and resources 
available. A number of additional optimisations are therefore possible which should be 
considered for future studies into this area. 
• Chromatographic separation of the vaccine tryptic peptides could be improved 
in the first instance through the use of ultra-high pressure chromatography 
(UHPLC) which is reported (Plumb et al., 2004) to give faster separation as well 
as better peak resolution compared to standard RP-HPLC; this would enable 
more accurate sample fractionation, increasing reproducibility and potentially 
increasing identification of low abundant proteins downstream.  
• The use of a more modern mass spectrometer, such as a linear ion trap orbitrap, 
could identify a larger number of proteins in the bacterial and vaccine proteomes 
due to an increased scan speed and mass accuracy (Olsen et al., 2009) compared 
to the Agilent 6520 Q-ToF.  
• Certain software improvements, such as automated exclusion lists which allow 
identified proteins to be excluded from subsequent reanalysis, could also 
dramatically increase the identification of proteins with low abundance 
(Hiemstra et al., 2011).  
• Similarly proteomic analysis of Leptospira interrogans serovar Canicola and 
derived vaccine products would also benefit from genetic sequencing of serovar 
Canicola. This would provide a serovar specific protein database against which 
resultant mass spectra could be searched. 
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In summary this study has achieved its aims and objectives by identifying LipL32 as a 
potential biomarker for efficacy in serovar Canicola vaccines and providing proof of 
principle for the use of N terminal LipL32 quantitation as a potential in vitro 
replacement for the existing hamster challenge serovar Canicola vaccine potency test. 
However further refinement and validation of this N terminal LipL32 assay will be 
required prior to replacement of the existing hamster challenge test. 
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